Document:

EX-10.1

 Exhibit 10.1 

ENTEROMEDICS INC. 

EMPLOYMENT AGREEMENT 
 THIS
EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered on October 3, 2016 (the “Agreement Date”), between ENTEROMEDICS INC. (“Company”), a Delaware corporation with its principal place of business at 2800
Patton Road, St. Paul, Minnesota 55113; and Scott P. Youngstrom (“Employee”), a Minnesota resident whose address is 4230 Mount Curve, Deephaven, MN 55331, for the purpose of setting forth the terms and conditions of Employee’s
employment by Company. 
 W I T N E S S E T H: 

WHEREAS, the Company desires to employ Employee as the Chief Financial Officer and Chief Compliance Officer of the Company, and
for Employee to hold such position, on the terms and conditions, and for the consideration, hereinafter set forth and Employee desires to be employed by the Company and hold such position on such terms and conditions and for such consideration; and

 WHEREAS, Employee executed a Nondisclosure and Noncompetition Agreement with the Company on October 3, 2016
(“Noncompetition Agreement”), which is attached as Exhibit A to this Agreement and fully incorporated herein. 
 NOW,
THEREFORE, for and in consideration of the mutual promises, covenants and obligations contained herein, the Company and Employee agree as follows: 

ARTICLE I 
 EMPLOYMENT,
TERM AND DUTIES 
 1.1 Employment. Company hereby employs Employee as its Chief Financial Officer and Chief Compliance Officer, and Employee
accepts such employment and agrees to perform services for Company pursuant to the terms and conditions set forth in this Agreement. 
 1.2 Term. The
term of this Agreement shall commence on the Agreement Date and, unless earlier terminated in accordance with Article III of this Agreement, shall terminate one year from the Agreement Date (the “Term”); provided, however, that the
Term of this Agreement shall automatically renew for successive one-year terms thereafter unless, at least 90 days before the expiration of the initial Term or any additional Term, either party provides
written notice to the other of its or his desire to terminate this Agreement. 
 1.3 Position and Duties. 

1.3.1 Service with Company. During the Term, Employee agrees to perform such duties and responsibilities as are assigned to him from
time to time by Company’s Chief Executive Officer (the “CEO”) and/or Board of Directors (the “Board”). 

 1.3.2 Performance of Duties. During the Term, Employee agrees to serve Company in an
executive capacity as its Chief Financial Officer and Chief Compliance Officer, and shall perform such duties as are required by the CEO and/or the Board. 

ARTICLE II 

COMPENSATION, BENEFITS AND EXPENSES 
 2.1
Base Salary. Subject to the provisions of Article III of this Agreement, during the Term, Company shall pay Employee a “Base Salary” of $300,000.00 on an annualized basis or such higher annual rate as may from time to time be
approved by the Board. Such Base Salary shall be paid in substantially equal regular periodic payments, less deductions and withholdings, in accordance with Company’s regular payroll procedures, policies and practices for executive officers, as
such may be modified from time to time. The Base Salary shall be reviewed by the Board annually for potential adjustment on the basis of performance; and Employee shall be eligible, at Company’s sole discretion, for annual salary increases
consistent with Company’s procedures, policies and practices. If Employee’s Base Salary is increased from time to time during the Term, the increased amount shall become the Base Salary for the remainder of the Term and any extensions of
the Term and for as long thereafter as required pursuant to Article III as applicable, subject to any subsequent increases. 
 2.2 Incentive
Compensation. In addition to Base Salary, Company shall make Employee eligible for such cash and equity awards pursuant to Company’s Incentive Compensation Plan, if any, as may be applicable and adopted by Company. Except to the extent as
otherwise provided in Article III in connection with a termination of Employee’s employment, payment of incentive compensation will be subject to Employee achieving certain objectives set annually by Employee and the Compensation Committee
of the Board, with the target amount of any cash incentive compensation for any calendar year to be approved by the Compensation Committee of the Board, which target in no event shall be more than 45% (subject to performance of the specified
objectives) of Employee’s Base Salary in effect from time to time. Employee and the Compensation Committee will meet and review the objectives set by the Compensation Committee for each upcoming calendar year before March 31 of such year.
Company shall pay any such incentive compensation for which Employee may be eligible for a calendar year on or before March 15 of the following year (provided that Employee is employed on such date). Employee will not be entitled to receive
incentive compensation for any calendar year in which Employee’s employment is terminated, except as may be provided in Article III. 
 2.3
Participation in Benefits. During the Term of Employee’s employment by Company, Employee shall be entitled to participate in the employee benefits offered generally by Company to its employees, to the extent that Employee’s
position, tenure, salary, health and other qualifications make Employee eligible to participate. Without limiting the foregoing, Employee shall be eligible to participate in any pension plan, or group life, health or accident insurance or any other
plan or policy that may presently be in effect or that may hereafter be adopted by Company for the benefit of its employees and/or corporate officers generally. Employee is eligible to receive four (4) weeks of vacation on an annual basis,
subject to Company’s “Paid Time Off” policy. Employee’s participation in such benefits shall be subject to the terms of the applicable plans, as the same may be amended from time to time. Company does not guarantee the adoption
or continuance of any particular employee benefit during Employee’s employment; and nothing in this Agreement is intended to, or shall in any way restrict the right of Company to amend, modify or terminate any of its benefit plans during the
Term of this Agreement. 

  
 2 

 ARTICLE III 

TERMINATION AND COMPENSATION FOLLOWING TERMINATION 

3.1 Termination. Subject to the respective continuing obligations of the parties under this Agreement, this Agreement and Employee’s employment
hereunder may be terminated as of the applicable date, whether before or at the end of the Term (the “Separation Date”) under any of the following circumstances: 

3.1.1 Termination by Mutual Agreement. By mutual written agreement of the parties at any time, which may specify a Separation Date. 

3.1.2 Termination by Employee’s Death. If Employee dies during the Term, the date of his death shall be his Separation Date. 

3.1.3 Termination Due to Employee’s Disability. If Employee becomes Disabled, the Separation Date shall be the effective date of
his resignation or his discharge by the Company because of the Disability, whichever occurs first. For purposes of this Agreement, “Disabled” or “Disability” means the incapacity or inability of Employee, whether due to accident,
sickness or otherwise (with the exception of the illegal use of drugs), to perform the essential functions of Employee’s position under this Agreement, with or without reasonable accommodation (provided that no accommodation that imposes undue
hardship on Company will be required) for an aggregate of 90 days during any period of 180 consecutive days, or such longer period as may be required under applicable law. 

If Employee (or his legal representative, if applicable) does not agree with the Company’s decision to terminate his employment hereunder
because of Disability, the question of Employee’s Disability shall be subject to the certification of a qualified medical doctor mutually agreed to by Company and Employee (or, in the event of Employee’s incapacity to designate a doctor,
Employee’s legal representative). In the absence of such agreement, each such party shall nominate a qualified medical doctor and the two doctors shall select a third doctor, who shall make the determination as to Employee’s Disability.
The decision of the designated physician shall be binding upon the parties in the same manner as the decision of an arbitrator under Section 4.5. 

3.1.4 Termination by Company for Cause. Company may terminate this Agreement and Employee’s employment for Cause immediately upon
written notice to Employee. For purposes of this Agreement, “Cause” means: (a) willful breach of Employee’s duties to Company or willful breach of this Agreement; (b) Employee’s conviction of any felony or any crime
involving fraud, dishonesty, or moral turpitude; (c) Employee’s willful participation in any fraud against or affecting Company or any subsidiary, affiliate, customer, supplier, client, agent, or employee thereof; or (d) any other act
that Company reasonably determines constitutes gross or willful misconduct materially detrimental to Company including, but not limited to, unethical practices, dishonesty, disloyalty, or any other acts harmful to Company; provided, however that a
for Cause termination pursuant to clause (a), if susceptible of cure, which determination is in the 

  
 3 

 
sole discretion of Company to make, shall not become effective unless Employee fails to cure such failure to perform or breach within 30 days after his receipt of written notice from
Company, such notice to describe such failure to perform or breach and identity what reasonable actions shall be required to cure such failure to perform or breach. 

For purposes of this Section 3.1.4, no act, or failure to act, on Employee’s part shall be considered “dishonest” or
“willful” unless done, or omitted to be done, by Employee in bad faith and without reasonable belief that his action or omission was in or not opposed to, the best interest of Company. Any act, or failure to act, based upon authority given
pursuant to a resolution duly adopted by the Board or based upon the advice of counsel for Company shall be conclusively presumed to be done, or omitted to be done, by Employee in good faith and in the best interests of Company. Furthermore, the
term “Cause” shall not include ordinary negligence or failure to act, whether due to an error in judgment or otherwise, if Employee has exercised substantial efforts in good faith to perform the duties reasonably assigned or appropriate to
his position. 
 3.1.5 Termination by Employee without Good Reason. Employee may at any time voluntarily terminate his employment
under this Agreement, for any reason or no reason, with 30 days’ written notice. 
 3.1.6 Termination by Company without
Cause. Company may terminate Employee’s employment under this Agreement at any time for any reason or no reason with 30 days’ written notice, except that no notice shall be required for a termination without Cause following a
“Change in Control” as defined in Employee’s Incentive Stock Option Agreement(s) or Non-Incentive Stock Option Agreement(s), as the case may be, with Company (collectively, the “Stock
Option Agreements”). 
 3.1.7 Termination by Employee for Good Reason. Employee may at any time voluntarily terminate his
employment pursuant to this Agreement for Good Reason (as defined below); provided, however, that any resignation by Employee for Good Reason shall not be effective unless and until the following two conditions have been satisfied: (a) he has
notified Company in writing of the facts that he believes constitute Good Reason, within 90 days after such facts first becomes known to him; and (b) Company fails to cure such Good Reason within 30 days after its receipt of that notice.
Employee’s resignation shall be effective before the end of that 30-day period as of any earlier date on which Company refuses to cure or denies the existence of such Good Reason. The effective date of
any resignation for Good Reason shall be a Separation Date. If Company timely cures such Good Reason, or it is determined that the reason for Employee’s resignation was not a Good Reason, he shall be deemed not to have resigned unless he elects
to resign under Section 3.1.5. 
 For purposes of this Agreement, “Good Reason” means, at any time: (a) the assignment
by Company to Employee of employment duties, functions or responsibilities that are significantly different from, and result in a substantial diminution of, Employee’s duties, functions or responsibilities, including without limitation any
requirement that Employee report to another officer of Company, rather than directly to the Board; (b) a material reduction in Employee’s Base Salary or the minimum target amount provided under Section 2.2 for his cash incentive
compensation for any calendar year; (c) a Company requirement that Employee be based at any office or location more than 25 miles from Employee’s primary work location before the date of this Agreement; or (d) any other action or
inaction that constitutes a material breach of this Agreement by Company. 

  
 4 

 3.1.8 Termination at End of Term. The termination of this Agreement and Employee’s
employment, as of the end of the initial Term or any additional Term, pursuant to the operation of the provisions of Section 1.2, shall entitle Employee only to the payments provided in Sections 3.2.1 and 3.3. 

3.2 Compensation following Termination of Employment. If Employee’s employment pursuant to this Agreement is terminated before the end of the
Term, or by Company as of the end of the Term, Employee shall be entitled to the following compensation and benefits upon such termination: 

3.2.1 Payment of Base Salary. If Employee’s employment is terminated pursuant to any subsection of Section 3.1, Company shall,
within 14 calendar days following the Separation Date, pay to Employee, Employee’s surviving spouse (or, if none, Employee’s estate), as the case may be, any amounts due to Employee for Base Salary through the Separation Date. 

If a termination occurs pursuant to Section 3.l.5 (by Employee without Good Reason), when Company receives Employee’s notice Company
shall have the option, at its discretion (a) to continue to engage Employee’s services through the 30 day notice period until the Separation Date, or (b) terminate the use of Employee’s services during the 30 day notice
period before the Separation Date but treat Employee as if he were providing services through the 30 day notice period until the Separation Date for purposes of determining Employee’s compensation due him pursuant to this
Section 3.2.1. 
 3.2.2 Payment of Severance for Termination by Company without Cause or by Employee for Good Reason. If
(a) Employee’s employment is terminated pursuant to either of Sections 3.1.6 (by Company without Cause) or 3.1.7 (by Employee for Good Reason), (b) Employee has executed and delivered to Company, within 60 days after the effective
date of that termination, a written release in substantially the same form as is attached hereto as Exhibit B, and (c) the rescission period specified therein has expired, Company shall, subject to any payment delay required by
Section 3.2.6, continue to pay, as severance pay, Employee’s Base Salary (at the rate in effect on the Separation Date, for a period of 12 months following the Separation Date, and Employee shall be permitted to exercise all shares that
are vested under his Options as of the Separation Date and those Options that would have vested within one year following the Separation Date immediately or at any time during the five-year period (but not
after the end of each Option’s original term) following the Separation Date. Such payments of Base Salary will be at the usual and customary pay intervals of Company and will be subject to all appropriate deductions and withholdings. For
purposes of Employee’s qualification for severance pay, his right to any series of such payments due under this Agreement is treated as the right to a series of separate payments, each of which is subject to all of the requirements of this
Section 3.2.2. 
 3.2.3 Payment of Severance at End of Term. If (a) Employee’s employment terminates pursuant to
Section 3.1.8, (b) Employee has executed and delivered to Company, 

  
 5 

 
within 60 days after the effective date of that termination, a written release in substantially the same form as is attached hereto as Exhibit B, and (c) the rescission period
specified therein has expired, Company shall, subject to any payment delay required by Section 3.2.6, continue to pay, as severance pay, Employee’s Base Salary at the rate in effect on the Separation Date, for a period of 12 months
following the Separation Date, and Employee shall be permitted to exercise all shares vested under his Options as of the Separation Date and those Options that would have vested within one year following the Separation Date immediately or at any
time during the five-year period (but not after the end of each Option’s original term) following the Separation Date. 

3.2.4 Effects of Change in Control. Upon the occurrence of a Change in Control (as defined in Section 3.1.6), Company agrees that,
notwithstanding any contrary provisions of the Stock Option Agreements or Company’s Stock Incentive Plan, the vesting schedule of Employee’s stock options granted in the Stock Option Agreements (the “Options”) shall accelerate
such that on the date the Change in Control is completed, 100% of any then-unvested shares subject to the Options held by Employee shall immediately vest; provided, however, that if, in
connection with the consummation of the transaction resulting in the Change in Control, Employee receives a cash payment with respect to each Option (after they become fully vested) equal to the difference or “spread’’ between (a) the
per share amount paid to holders of Company’s common stock in such transaction and (b) the per share exercise price under the applicable Stock Option Agreement, his Options shall be cancelled upon the consummation of the Change in Control in
exchange for such cash payment; provided, further, that if in connection with or within the first two years after the Change in Control (as defined in Section 3.1.6), Employee’s employment is terminated pursuant to either of
Sections 3.1.6 (by Company without Cause) or 3.1.7 (by Employee for Good Reason), and (a) Employee has executed and delivered to Company, within 60 days after the effective date of that termination, a written release in substantially the same form
attached hereto as Exhibit B, and (b) the rescission period specified therein has expired, then, in addition to the payments under Section 3.2.2: 

(A) within 14 calendar days following the Separation Date, the Company shall also pay to Employee, or Employee’s surviving spouse (or, if
none, Employee’s estate), as the case may be, any amounts to which Employee is entitled as of the Separation Date, as a pro rata portion of any unpaid cash incentive compensation determined under Section 2.2 for the calendar year in which
the Separation Date occurs. That pro rated cash incentive compensation shall be based on whether Employee’s objectives were achieved (also pro rated to the extent possible) during the portion of the year before the Separation Date; and the pro
rated amount shall be based on the number of days in that portion, as compared with the entire year; and 
 (B) the vesting schedule of
Options held by Employee shall accelerate such that on the Separation Date connected with or after a Change in Control, 100% of any unvested shares under the Options shall immediately vest and shall be exercisable immediately or at any time during
the five-year period (but not after the end of each Option’s original term) following the Separation Date, notwithstanding any contrary provisions of the Stock Option Agreements or Company’s Stock
Incentive Plan; provided, however, that if, in connection with the consummation of the transaction resulting in the Change in Control, Employee receives a cash payment with respect to each Option (after they become fully vested under this paragraph)
equal to the difference or “spread” between (a) the per share amount paid to holders of Company’s 

  
 6 

 
common stock in such transaction and (b) the per share exercise price under the applicable Stock Option Agreement, his Options shall be cancelled upon the consummation of the Change in
Control in exchange for such cash payment. The parties hereto agree and acknowledge that, with respect to any Options previously granted to Employee that were intended by the parties to be treated as “incentive stock options” within the
meaning of Code Section 422, such Options, to the extent they may be exercised by Employee more than 90 days following the Separation Date, shall be treated as non-qualified Options, notwithstanding
any contrary provisions of the Stock Option Agreements. 
 3.2.5 General Provision Regarding Treatment of Options. Except as
otherwise specified in Sections 3.2.2 and 3.2.4 of this Agreement, the terms of the Stock Incentive Plan and Stock Option Agreements, as applicable, shall govern the treatment of the Options following the Separation Date. 

3.2.6 Potential Delay of Severance Payments. If, as of the Separation Date, (a) Company’s common stock is publicly traded (as
determined under Code Section 409A), (b) Employee is a “specified employee” (as determined under Code Section 409A), and (c) any portion of the severance pay due Employee under Sections 3.2.2, 3.2.3 (and, if
applicable, paragraph (A) of Section 3.2.4) would exceed the sum of the applicable limited separation pay exclusions (or otherwise not qualify for any exclusion) as determined pursuant to Code Section 409A, then payment of the excess
amount shall be delayed until the first regular payroll date of Company following the six month anniversary of Employee’s Separation Date (or the date of his death, if earlier than that anniversary), and shall include a lump sum equal to the
aggregate amounts that Employee would have received had payment of this excess amount commenced as provided in Sections 3.2.2, 3.2.3 (and, if applicable, paragraph (A) of Section 3.2.4) after the Separation Date. If Employee continues
to perform any services for Company (as an employee or otherwise) after the Separation Date, such six month period shall be measured from the date of Employee’s “separation from service” as defined pursuant to Code Section 409A.
Each payment under this Agreement shall be treated as a separate payment for purposes of Code Section 409A. 
 3.3 Benefits Following Certain Employment
Terminations. If Employee’s employment is terminated pursuant to any of Sections 3.1.2, 3.1.3, 3.1.6, 3.l.7 or 3.1.8, Company shall provide, at the sole cost of Company (except for any share of the cost for benefits for Employee and
Employee’s spouse and any eligible dependents that Employee was required to pay immediately before the Separation Date), continuing coverage under any of its medical, dental and life insurance programs for Employee (if Employee survives) and
Employee’s spouse and any eligible dependents, to the extent any such coverage was in effect for any of those individuals immediately before the Separation Date and is extended under COBRA. The Company’s provision of continuing coverage
will end after the greater of the following periods: (a) if applicable, the period during which Employee is entitled to receive his Base Salary as severance pay under Section 3.2.2 or 3.2.3; or (b) the first 12 months after the
Separation Date, irrespective of any then pre-existing health conditions of Employee, Employee’s spouse or any eligible dependents; provided, however, that Company may discontinue any such coverage for
which it does not receive timely payment of Employee’s share of the cost due after the Separation Date; and provided further that, in each case, such continued participation is not prohibited by any applicable laws or would not otherwise
jeopardize the tax qualified status of any such programs. All reimbursement under this Section 3.3 shall terminate upon commencement of new 

  
 7 

 
employment by Employee with an employer that offers health care coverage to its employees. If any such continuing participation is prohibited by applicable law or would otherwise jeopardize the
tax qualified status of any medical, dental or life insurance plan and, as a result, Company terminates any such coverage, it shall promptly reimburse Employee (or Employee’s spouse and eligible dependents, as the case may be) for the cost of
obtaining comparable third party coverage irrespective of any then preexisting health conditions of any of them who was covered immediately before the Separation Date. Any period of continuing coverage under this Section 3.3 shall run at the
same time as the applicable continuing coverage required to be offered to Employee, Employee’s spouse or eligible dependents under applicable laws. 

Except as otherwise provided in this Section 3.3, the benefits to which Employee (or, as applicable, Employee’s spouse, eligible dependents or
estate) may be entitled upon termination of his employment, pursuant to the plans and policies of Company described in Article II of this Agreement, shall be determined and paid in accordance with such plans, policies and applicable laws. 

3.4 Surrender of Records and Property. Upon termination of Employee’s employment with Company, Employee shall deliver promptly to Company all
Confidential Information as defined in Section 4.1 and all Company property including, but not necessarily limited to records, manuals, books, blank forms, documents, letters, memoranda, business plans, minutes, notes, notebooks, reports,
computer disks, computer software, computer programs (including source code, object code, on-line files, documentation, testing materials and plans and reports), computer
print-outs, member or customer lists, credit cards, keys, identification, products, access cards, designs, drawings, sketches, devices, specifications, formulae, data, tables or calculations or copies thereof,
and all other tangible or intangible property relating in any way to the business of Company that are the property of Company or any subsidiary or affiliate, if any, or which relate in any way to the business, products, practices or techniques of
Company or any subsidiary or affiliate. 
 ARTICLE IV 

MISCELLANEOUS PROVISIONS 
 4.1 Company
Remedies. Employee acknowledges and agrees that the restrictions and agreements contained in this Agreement and in the Noncompetition Agreement that is attached as Exhibit A to this Agreement are reasonable and necessary to protect legitimate
interests of Company; that the services to be rendered by Employee are of a special, unique and extraordinary character; that it would be difficult to replace such services; that any violation of the Noncompetition Agreement would be highly
injurious to Company; that Employee’s violation of the Noncompetition Agreement would cause Company irreparable harm that would not be adequately compensated by monetary damages; and that the remedy at law for any breach of any of the
provisions of the Noncompetition Agreement will be inadequate. Accordingly, Employee specifically agrees that Company shall be entitled, in addition to any remedy at law, to preliminary and permanent injunctive relief and specific performance for
any actual or threatened violation of this Agreement and to enforce the provisions of the Noncompetition Agreement. 

  
 8 

 4.2 Assignment. This Agreement shall not be assignable, in whole or in part, by Employee without the
written consent of Company and any purported or attempted assignment or transfer of this Agreement or any of Employee’s duties, responsibilities or obligations hereunder shall be void. This Agreement shall inure to the benefit of and be binding
upon Employee, Employee’s heirs and personal representatives. This Agreement shall inure to the benefit of and be binding upon Company and its successors and assigns. Notwithstanding the foregoing, Company may not, without the written consent
of Employee, assign its rights and obligations under this Agreement to any business entity that has become the successor to Company in the event of a sale, merger, liquidation or similar transaction. After any such assignment by Company to which
Employee has given such consent, Company shall be discharged from all further liability hereunder and such successor assignee shall thereafter be deemed to be Company for the purposes of all provisions of this Agreement. 

4.3 Notices. All notices, requests, demands and other communications under this Agreement shall be in writing, shall be deemed to have been duly given
on the date of service if personally served on the parties to whom notice is to be given, or on the third day after mailing if mailed to the parties to whom notice is given, whether by first class, registered, or certified mail, and properly
addressed as follows: 
  

					
		 	If to Company, at:	  	 EnteroMedics Inc.
 2800 Patton Road

St. Paul, MN 55113

			
		 	If to Employee, at:	  	 Scott P Yougstrom
 4230 Mount Curve

Deephaven, MN 55331

 Any party may change the address for the purpose of this Section by giving the other written notice of the new address in the
manner set forth above. 
 4.4 Governing Law/Venue. The validity, interpretation, performance and enforcement of this Agreement shall be governed by
the laws of the State of Minnesota, without regard to conflicts of laws principles thereof. The parties irrevocably consent and agree that the venue of any cause of action seeking injunctive relief shall be Minnesota District Court, Hennepin County,
and the parties further irrevocably consent to the personal jurisdiction of the Minnesota District Court for any such action. 
 4.5 Arbitration. The
parties irrevocably consent that, except to the extent provided in this section and Section 4.4, any litigation or other dispute arising between the parties, in connection with the interpretation or enforcement of this Agreement, that has not
been settled through negotiation within a period of 30 days after the date on which either party shall first have notified the other party in writing of the existence of the dispute, shall be settled by final and binding arbitration under the then-applicable Employment Arbitration Rules of the American Arbitration Association (“AAA”); and a court judgment on the award may be entered in any court having competent jurisdiction. Notwithstanding
the foregoing, neither party shall be entitled or required to seek arbitration regarding any cause of action that would entitle such party to injunctive relief. 

  
 9 

 Any such arbitration shall be conducted by one neutral arbitrator appointed by mutual agreement of the parties
or, failing such agreement, in accordance with the AAA Rules. The arbitrator shall be an experienced attorney with a background in employment law. Any arbitration shall be conducted in Minneapolis, Minnesota. An arbitration award may be enforced in
any court of competent jurisdiction. Notwithstanding any contrary provision in the AAA Rules, the following additional procedures and rules shall apply to any such arbitration: 

 

	 	(a)	Each party shall have the right to request from the arbitrator, and the arbitrator shall order upon good cause shown, reasonable and limited pre-hearing discovery, including:
(i) exchange of witness lists, (ii) no more than two (2) depositions under oath of named witnesses at a mutually convenient location (neither deposition to exceed seven (7) hours), (iii) written interrogatories (no more than
twenty-five (25) in number), and (iv) document requests (no more than twenty-five (25) in number, including subparts); 

  

	 	(b)	Upon conclusion of the pre-hearing discovery, the arbitrator shall promptly hold a hearing upon the evidence to be adduced by the parties and shall promptly render a written
opinion and award; 

  

	 	(c)	The arbitrator may award damages consistent with the terms of this Agreement but may not award or assess punitive damages against either party; and 

 

	 	(d)	Each party shall bear 50% of the fees and costs of the arbitrator, subject to the power of the arbitrator, in his or her sole discretion, to award all such fees and costs to the prevailing party. 

4.6 Construction. Notwithstanding the general rules of construction, both Company and Employee acknowledge that both parties were given an equal
opportunity to negotiate the terms and conditions contained in this Agreement, and agree that the identity of the drafter of this Agreement is not relevant to any interpretation of the terms and conditions of this Agreement. 

To the extent any provision of this Agreement may be deemed to provide a benefit to Employee that is treated as
non-qualified deferred compensation pursuant to Code Section 409A, such provision shall be interpreted in a manner that qualifies for any applicable exemption from compliance with Code Section 409
or, if such interpretation would cause any reduction of benefit(s), such provision shall be interpreted (if reasonably possible) in a manner that complies with Code Section 409A and does not cause any such reduction. 

4.7 Severability. In the event any provision of this Agreement (or portion thereof) shall be held illegal or invalid for any reason, said illegality or
invalidity shall not in any way affect the legality or validity of any other provision of this Agreement. To the extent any provision (or portion thereof) of this Agreement shall be determined to be invalid or unenforceable in any jurisdiction, such
provision (or portion thereof) shall be deemed to be deleted from this Agreement as to such jurisdiction only, and the validity and enforceability of the remainder of such provision and of this Agreement shall be unaffected. 

4.8 Entire Agreement. This Agreement, including the Noncompetition Agreement that is attached as its Exhibit A and fully incorporated herein, is the
final, complete and exclusive 

  
 10 

 
agreement of the parties and sets forth the entire agreement between Company and Employee with respect to Employee’s employment by Company, and there are no undertakings, covenants or
commitments other than as set forth herein. The Agreement may not be altered or amended, except by a writing executed by Employee and a member of the Board. This Agreement supersedes, terminates, replaces and supplants any and all other prior
understandings or agreements between the parties relating in any way to the hiring or employment of Employee by Company. 
 4.9 Survival. The parties
expressly acknowledge and agree that the provisions of this Agreement that by their express or implied terms extend beyond the expiration of this Agreement or the termination of Employee’s employment under this Agreement, shall continue in full
force and effect, notwithstanding Employee’s termination of employment under this Agreement or the expiration of this Agreement. 
 4.10
Waivers. No failure on the part of either party to exercise, and no delay in exercising, any right or remedy under this Agreement shall operate as a waiver thereof; nor shall any single or partial exercise of any right or remedy under this
Agreement preclude any other or further exercise thereof or the exercise of any other right or remedy granted hereby or by any related document or by law. 

4.11 Attorneys’ Fees for Negotiating Agreement. Upon receipt by Company of a statement for legal services from the attorneys representing
Employee, Company shall reimburse Employee or pay on behalf of Employee the reasonable and necessary attorneys’ fees and associated expenses incurred by Employee in connection with the negotiation of this Agreement, provided, that such fees and
expenses shall not exceed $5,000.00. 
 4.12 Attorneys’ Fees for Resolving Disputes. If any party to this Agreement is made or shall become a
party to any litigation (including arbitration) commenced by or against the other party involving the enforcement of any of the rights or remedies of such party, or arising on account of a default of the other party in its performance of any of the
other party’s obligations hereunder, then the prevailing party in such litigation shall be entitled to receive from the other party all costs incurred by the prevailing party in such litigation, plus reasonable attorneys’ fees to be fixed
by the court or arbitrator (as applicable), with interest thereon from the date of judgment or arbitrator’s decision at the rate of 8% or, if less, the maximum rate permitted by law. 

[Signature Page Follows] 

  
 11 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

  

			
	ENTEROMEDICS INC.
		
	By	 	/s/ Dan W. Gladney
		 	Its: Chief Executive Officer

 
			
	
	/s/ Scott P. Youngstrom
	Scott P. Youngstrom

  
 12 

 Exhibit A 

Nondisclosure and Noncompetition Agreement 

(attached) 

 EnteroMedics Inc. 

Nondisclosure and Noncompetition Agreement 

This is an agreement between Scott Youngstrom (“Employee”) and EnteroMedics Inc., its affiliates, successors and assigns (“Employer”). The
parties agree that Employer would be substantially harmed if Employee competes with Employer during employment with Employer or after termination of employment with Employer. The parties further agree that Employer would be substantially harmed if
Employee were to disclose its Confidential, Proprietary and Trade Secret Information. 
 Therefore, in consideration of Employer’s employment of
Employee for monetary compensation, benefits, access to Employer’s Trade Secrets and/or Confidential Information, and/or other valuable consideration provided by Employer, Employee agrees as follows: 

I. Nondisclosure of Confidential, Proprietary, and Trade Secret Information 

Employee agrees not to disclose Confidential Information to any other third party or company, other than in connection with Employee’s employment with
Employer, or use such information, directly or indirectly, for any purpose whatsoever, without the prior written consent of Employer. 
 For purposes of
this Agreement, “Confidential Information” means any information that is not generally known to the public or to other persons who can obtain economic value from its disclosure or use; information which derives independent economic benefit
from not being known to such persons; and information about the activities or business of Employer that is not generally known to others engaged in similar business or activities, its products, services, finances, trade secrets, contracts, patents
filed or pending, the techniques used in completing customer projects, research and development, data and information, processes, designs, engineering, marketing plans or techniques, organization or operation. The foregoing list is intended to be
illustrative rather than comprehensive. Additionally, the term “confidential information” shall mean any confidential information as that term is defined in any Agreement Employer may have with its customers or other third parties from
time to time. 
 II. Assignment of Inventions 
  

	A)	 Disclosure and Assignment of Inventions and Other Works. During the term of this Agreement and for one
year following the Separation Date, Employee shall promptly disclose to Employer in writing all ideas, improvements and discoveries, whether or not such are patentable or copyrightable, and whether or not in writing or reduced to practice
(“Inventions”) and any writings, drawings, diagrams, charts, tables, databases, software (in object or source code and recorded on any medium), and any other works of authorship, whether or not such are copyrightable (“Works of
Authorship”) that are conceived, made, discovered, written or created by Employee alone or jointly with any person, group or entity, whether during the normal hours of his employment at Employer or on Employee’s own time. Employee hereby
assigns all rights to all such Inventions and Works of Authorship to Employer. Employee shall give Employer all the assistance it reasonably requires for Employer to perfect, protect, and use its rights to such

	 	
Inventions and Works of Authorship. Employee shall sign all such documents, take all such actions and supply all such information that Employer considers necessary or desirable to transfer or
record the transfer of Employer’s entire right, title and interest in such Inventions and Works of Authorship and to enable Employer to obtain exclusive patent, copyright, or other legal protection for Inventions and Works of Authorship
anywhere in the world, provided Employer shall bear all reasonable expenses of Employee in rendering such cooperation. 

  

	B)	Prior Inventions. Employee has set forth on Exhibit A attached hereto a list of all significant Inventions, to the best of his knowledge, that Employee has, alone or jointly with others, made prior to his
employment with Employer that Employee considers to be Employee’s property or the property of third parties and that Employee wishes to exclude from the scope of this Agreement (collectively referred to as “Prior Inventions”). If no
such disclosure is attached, or permission supporting evidence is available, Employee represents that there are no Prior Inventions. If, during Employee’s employment with Employer, Employee incorporates a Prior Invention into an Employer
product or process, Employer is hereby granted a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license (with rights to sublicense through multiple tiers of sublicenses) to make, have made, modify, use and sell such Prior Invention.
Notwithstanding the foregoing, Employee agrees that Employee will not incorporate, or permit to be incorporated, Prior Inventions in any Employer Inventions without Employer’s prior written consent. 

 

	C)	Notice and Acknowledgement. In accordance with Minnesota Statute § 181.78, the foregoing paragraph does not require Employee to assign or offer to assign to Employer any of Employee’s rights in an
Invention that Employee developed entirely on Employee’s own time without using Employer’s equipment, supplies, facilities or trade secret information, and (a) that does not relate directly to Employer’s business or to
Employer’s actual or demonstrably anticipated research or development, or (b) that does not result from any work performed by Employee for Employer. For the purpose of this Section, “Employer’s business” shall be defined as
development pertaining to implantable medical devices to treat obesity or devices to apply signals to a vagus nerve to treat a gastrointestinal disorder (e.g., obesity, pancreatitis or irritable bowel syndrome). 

 

	  	To the extent a provision in this Agreement purports to require Employee to assign Inventions otherwise excluded by this paragraph, the provision is against the public policy of the State of Minnesota and is
unenforceable. By signing this Agreement, Employee acknowledges receipt of the notification required by Minnesota Statute § 181.78. 

III. Noncompete and Nonsolicitation 
  

	A)	 Agreement Not to Compete. During the Term of Employee’s employment by Employer, and for a period of
12 consecutive months from the date of Termination of such employment for whatever reason (whether occasioned by Employee or Employer), Employee shall not, directly or indirectly, in any place in the world, render services to any conflicting
organization, or engage in competition with Employer, in any manner or 

  
 2 

	 	
capacity, nor direct any other individual or business enterprise to engage in, competition with Employer in any manner or capacity, (e.g., as an advisor, principal, agent, partner, officer,
director, stockholder of more than 1% of the outstanding shares of the capital stock of a publicly traded company, employee, member of any association or limited liability company or otherwise) on any products competitive with Employer’s
existing products, any products competitive with Employer’s announced products or any products competitive with Employer’s pending products that have not yet been announced but which Employee has, or should have, actual or constructive
knowledge. For the purposes of this Section, “conflicting organization” shall be defined as any person, corporation or entity that competes with any product, process or service, in existence or under development, of Employer pertaining to
implantable medical devices to treat obesity or devices to apply signals to a vagus nerve to treat a gastrointestinal disorder (e.g., obesity, pancreatitis or irritable bowel syndrome). 

 

	B)	Agreement Not to Solicit. Employee hereby acknowledges that Employer’s customers constitute vital and valuable aspects of its business on a worldwide basis. In recognition of that fact, for a period of one
year following the termination of this Agreement for any reason whatsoever, Employee shall not solicit, or assist anyone else in the solicitation of, any of Employer’s then-current customers to terminate
their respective relationships with Employer and to become customers of any enterprise with which Employee may then be associated, affiliated or connected. 

  

	C)	Agreement Not to Recruit. Employee hereby acknowledges that Employer’s employees, consultants and other contractors constitute vital and valuable aspects of its business and missions on a worldwide basis. In
recognition of that fact, for a period of one year following the termination of this Agreement for any reason whatsoever, Employee shall not solicit, or assist anyone else in the solicitation of, any of Employer’s
then-current employees, consultants and other contractors to terminate their respective relationships with Employer and to become employees, consultants and other contractors of any enterprise with which
Employee may then be associated, affiliated or connected. 

 IV. Employer Remedies 

Employee acknowledges and agrees that the restrictions and agreements contained in this Agreement are reasonable and necessary to protect legitimate interests
of Employer, that the services to be rendered by Employee are of a special, unique and extraordinary character, that it would be difficult to replace such services, that any violation of this Agreement would be highly injurious to Employer,
Employee’s violation of any provision of this Agreement would cause Employer irreparable harm that would not be adequately compensated by monetary damages, and that the remedy at law for any breach of this Agreement will be inadequate.
Accordingly, Employee specifically agrees that Employer shall be entitled, in addition to any remedy at law, to preliminary and permanent injunctive relief and specific performance for any actual or threatened violation of this Agreement and to
enforce the provisions of this Agreement. Should a breach of the agreement occur, Employer will be entitled to recover costs, including attorney’s fees, incurred in enforcing the terms of the Agreement for each breach. If a Court finds any part
of the Agreement to be invalid, the remainder of the provisions shall remain in full force and effect to the extent possible. 

  
 3 

 V. Governing Law/Venue 

The validity, interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Minnesota, without regard to
conflicts of laws principles thereof. The parties irrevocably consent and agree that the venue of any cause of action seeking injunctive relief shall be Minnesota District Court, Hennepin County, and the parties further irrevocably consent to the
personal jurisdiction of the Minnesota District Court for any such action. 
 VI. Construction 

Notwithstanding the general rules of construction, both Employer and Employee acknowledge that both parties were given an equal opportunity to negotiate the
terms and conditions contained in this Agreement, and agree that the identity of the drafter of this Agreement is not relevant to any interpretation of the terms and conditions of this Agreement. 

VII. Severability 
 In the event any provision of this
Agreement (or portion thereof) shall be held illegal or invalid for any reason, said illegality or invalidity shall not in any way affect the legality or validity of any other provision of this Agreement. To the extent any provision (or portion
thereof) of this Agreement shall be determined to be invalid or unenforceable in any jurisdiction, such provision (or portion thereof) shall be deemed to be deleted from this Agreement as to such jurisdiction only, and the validity and
enforceability of the remainder of such provision and of this Agreement shall be unaffected. 
 VIII. Waiver 

Failure by Employer to enforce any provision of this Agreement will not constitute a waiver of or a prohibition against any further enforcement of that
provision or any other provision of this Agreement. 
 IX. Entire Agreement and Amendment 

This Agreement supersedes all previous agreements between the parties concerning the subject matter of this Agreement. All amendments to this Agreement must be
in writing and signed by the parties to be effective. 
 X. At Will Employment 

This Agreement is not an employment agreement for any specified period of time and Employee understands that either Employee or Employer may terminate the
employment relationship at any time and for any reason or no reason at all. 
 XI. Succession and Survival 

This Agreement and the rights, duties and obligations of this Agreement shall survive the termination of Employee’s employment with Employer and shall
inure to the benefit of and shall be binding upon Employee’s heirs, assigns and personal representatives and the successors of Employer. 

  
 4 

 Executed this 3rd day of October, 2016. 

 

			
	EMPLOYEE
		
	By:	 	/s/ Scott P. Youngstrom
	Printed Name: Scott P. Youngstrom

  

			
	ENTEROMEDICS INC.
		
	By:	 	/s/ Dan W. Gladney
	Printed Name: Dan W. Gladney
	Its: Chief Executive Officer

  
 5 

 EXHIBIT A 

 

			
	To:	 	EnteroMedics Inc.
		
	From:	 	 
		
	Date:	 	 
		
	Subject:	 	Prior Inventions

  

	1.	Except as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter of my employment by EnteroMedics, Inc. (“Employer”) that have been
made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by Employer: 

  

	☒	No inventions or improvements. 

  

	☐	See below: 

  

			
		 	  

		
		 	  

		
		 	  

		
		 	  

  

	☐	Additional sheets attached 

  

	2.	Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to inventions or improvements generally listed below, the proprietary rights and duty of confidentiality
with respect to which I owe to the following parties: 

  

									
		 		  	Invention or Improvement	  	Party(ies)	  	Relationship
					
		 	1.	  	  
	  	  
	  	  

					
		 	2.	  	  
	  	  
	  	  

					
		 	3.	  	  
	  	  
	  	  

  

	☐	Additional sheets attached 

  
 6 

 EXHIBIT B 

CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE 

This Confidential Separation Agreement and General Release (hereinafter “Agreement”) is entered into by and between
                     (hereinafter “you”) and EnteroMedics Inc. (hereinafter “EnteroMedics”). 

WHEREAS, you and EnteroMedics entered into an Employment Agreement dated
                     (“Employment Agreement”) which terminates effective
                    , except as to certain provisions outlined below; 

WHEREAS, EnteroMedics wishes to provide you with the separation benefits described in Section 2 below;
and 
 WHEREAS, you and EnteroMedics want to fully and finally settle all issues, differences, and
claims, whether potential or actual, between you and EnteroMedics, including, but not limited to, any claim that might arise out of your employment with EnteroMedics or the termination of your employment with EnteroMedics; 

NOW, THEREFORE, in consideration of the provisions and of the mutual covenants contained herein, you and EnteroMedics agree as
follows: 
 1. Separation from Employment. Effective
                     (your “date of separation”), your employment with EnteroMedics terminates. Except as provided in this
Agreement, all benefits and privileges of employment end as of your date of separation. 
 2. Separation Benefits. As consideration
for your promises and obligations under this Agreement, and subject to the terms and conditions of this Agreement, including the release of claims set forth below, EnteroMedics agrees to pay you, as separation pay, the gross amount of
                    , less applicable deductions and withholdings for state and federal taxes, which amount represents 12 months of your
base salary as of your date of separation. The separation pay will be divided and paid to you in substantially equal periodic payments at the usual and customary pay intervals of EnteroMedics, less deductions and withholdings. The payments will
begin within 30 business days of the date on which EnteroMedics receives this Agreement signed by you, provided that you do not revoke or rescind this Agreement as set forth below. You agree that you are not entitled to the separation
benefits provided to you in this Agreement if you do not sign this Agreement. 
 3. Incentive Compensation. You are not entitled to
receive incentive compensation for calendar year                     . 

4. Medical, Dental, and Life Insurance. If you elect to extend EnteroMedics-provided medical, dental, and/or life insurance coverage
under COBRA after your date of separation, then EnteroMedics will provide, at its sole cost (except for any share of the cost for benefits for you and your spouse and any eligible dependents that you were required to pay immediately before your date
of separation) such extended coverage for you and your spouse and any eligible dependents, to the extent any such coverage was in effect for any of you and those individuals immediately before your date of separation, for 12 calendar months after
your date of separation. EnteroMedics’ obligations under this Section 4 shall terminate upon commencement 

 
of new employment by you with an employer that offers health care coverage to its employees. You agree that any COBRA premium paid on your behalf and/or any reimbursement made to you for COBRA
premiums paid by you will be treated as taxable by EnteroMedics. Except as otherwise provided in this Section 4, the benefits to which you (or, as applicable, your spouse and eligible dependents) may be entitled upon termination of your
employment shall be determined and paid in accordance with such plans, policies and applicable laws. 
 5. Stock Options. All options
to purchase shares of common stock of EnteroMedics held by you (the “Options”) are subject to the terms of one or more Stock Option Agreements between you and the Company (each, an “Option Agreement”) and were granted pursuant to
the EnteroMedics Inc. Amended and Restated 2003 Stock Incentive Plan, as amended (the “Plan”). Pursuant to the terms and conditions set forth in the Option Agreements, EnteroMedics agrees that, notwithstanding anything to the contrary set
forth in such Option Agreements or the Plan, during the two-year period following your date of separation, you shall be permitted to exercise any Option immediately to the extent that such Option was vested as of your date of separation or would
have vested within one year of your date of separation had your employment with Company not terminated. Notwithstanding anything to the contrary set forth in such Option Agreements or the Plan, EnteroMedics shall have a right, following your date of
separation, to buy back all such Options based on the per share exercise price under the applicable Option Agreement. The parties agree and acknowledge that, with respect to any Options that were intended by the parties to be treated as
“incentive stock options” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, such Options, to the extent they may be exercised by you more than 90 days following your date of separation, shall be
treated as non-qualified options, notwithstanding any provision in the Option Agreements to the contrary. 
 6. Confidential Information;
Noncompetition and Nonsolicitation. You executed an Executive Employment Agreement with EnteroMedics, a copy of which is attached hereto as Exhibit A. All provisions of the Employment Agreement that, by their terms, survive the termination of
your employment will continue in full force and effect and are not negated or otherwise affected by this Agreement, including but not limited to Section 4.1: Company Remedies; Section 4.4: Governing Law/Venue; Section 4.5:
Arbitration; and the Nondisclosure and Noncompetition Agreement attached to the Employment Agreement as its Exhibit A and fully incorporated therein. 

7. Return of EnteroMedics Property. You acknowledge that, on or before the date you sign this Agreement, you have returned all
EnteroMedics property in your possession, including, but not limited to, all files, memoranda, documents, records, copies of the foregoing, any EnteroMedics credit card, computer, fax machine, printer, copier, keys, access cards, and any other
property of EnteroMedics in your possession. You also acknowledge that, on or before the date you sign this Agreement, you have provided EnteroMedics with any and all pass codes and/or personal identification numbers used by you to access the
EnteroMedics computer system, e-mail system, and/or the Internet, and/or documents or files contained on and saved in the EnteroMedics computer system. 

8. Duty to Cooperate. You agree that, beginning on the date you are presented with this Agreement, you will cooperate with EnteroMedics
with respect to the transition of your duties, the preservation of effective operations and customer service, and EnteroMedics’ 

  
 2 

 
strategic and commercial initiatives. As part of your agreement to cooperate, you will provide a list identifying the status of major projects under way, pending customer interactions, the status
of sale cycles with customers, the names and contact information of key contacts at customers, and any other information reasonably requested by EnteroMedics regarding your duties and responsibilities. You further agree that, in the 30 day period
following your acceptance of this Agreement you will periodically make yourself accessible and available during normal business hours for consultation with EnteroMedics representatives in connection with the transition of your duties and
responsibilities. You agree that such consultation may include appearing from time to time at the office of EnteroMedics for conferences. 

9. Confidentiality. You agree that the existence and terms and conditions of this Agreement (other than Exhibit A) shall remain
confidential and that you will not disclose any information concerning the provisions of this Agreement to any person or entity, including, but not limited to, any present or former employee of EnteroMedics. These confidentiality provisions are
subject to the following exceptions: you may disclose the provisions of this Agreement to your attorneys, accountants, tax and financial advisors, and immediate family, or in the course of legal proceedings involving EnteroMedics, or in response to
a subpoena, court order, or inquiry by a government agency. You further agree that, if any information concerning the provisions of this Agreement is revealed as permitted by this section, you shall inform the recipient of the information that it is
confidential, and the recipient shall agree to keep the information confidential. 
 10. Release. By this Agreement, you intend to
settle any and all claims that you have or may have against EnteroMedics as a result of EnteroMedics hiring you, your employment with EnteroMedics, and the decision to terminate your employment with EnteroMedics. You agree that, in exchange for
EnteroMedics’ promises in this Agreement, and in exchange for the consideration provided to you by EnteroMedics, described above in Section 2, you, on behalf of your heirs, successors and assigns, hereby release and discharge EnteroMedics,
its predecessors, successors, assigns, parents, affiliates, subsidiaries, and related companies, and their officers, directors, shareholders, agents, servants, employees, and insurers (collectively “the Released Parties”) from all
liability for damages and from all claims that you may have against the Released Parties occurring up through the date you sign this Agreement. You understand and agree that your release of claims in this Agreement includes, but is not limited to,
any claims you may have under: Title VII of the Federal Civil Rights Act of 1964, as amended; the Americans with Disabilities Act; the Equal Pay Act; the Employee Retirement Income Security Act; the Age Discrimination in Employment Act of 1967, as
amended; the Older Workers Benefit Protection Act; the Family and Medical Leave Act; the Worker Adjustment and Retraining Notification Act of 1988; the False Claims Act; the Minnesota Human Rights Act; Minnesota Equal Pay for Equal Work Law, Minn.
Stat. §§ 181.66–181.71; Minn. § 181.81 (age discrimination); Minn. Stat. § 176.82 (retaliatory discharge); Minn. Stat. §§ 181.931, 181.932, 181.935 (whistleblower protection); Minn. Stat. §§
181.940–181.944 (family leave); or any other federal, state, or local statute, ordinance, or law. 
 You also agree and understand that you are giving
up all other claims, whether grounded in contract or tort theories, including but not limited to: wrongful discharge; breach of contract; any claim for unpaid compensation (including, but not limited to, any claims for PTO or severance except as set
forth in this Agreement, or for incentive compensation); tortious 

  
 3 

 
interference with contractual relations; promissory estoppel; detrimental reliance; breach of the implied covenant of good faith and fair dealing; breach of express or implied promise; breach of
manuals or other policies; breach of fiduciary duty; assault; battery; fraud; false imprisonment; invasion of privacy; intentional or negligent misrepresentation; defamation, including libel, slander, discharge defamation and self-publication
defamation; discharge in violation of public policy; whistleblower; qui tam actions; intentional or negligent infliction of emotional distress; or any other theory, whether legal or equitable. 

You understand that nothing contained in this Agreement, including but not limited to this Section 10, will be interpreted to prevent you from filing a
charge with the Equal Employment Opportunity Commission (“EEOC”), or any other governmental agency, or from participating in or cooperating with an EEOC or other governmental agency investigation or proceeding. However, you agree that you
are waiving the right to monetary damages or other individual legal or equitable relief awarded as a result of any such proceeding. 
 11.
Time to Accept. You are hereby informed that the terms of this Agreement shall be open for acceptance and execution by you through and including
                    , during which time you may consult with an attorney and consider whether to accept this Agreement. Changes to this
Agreement, whether material or immaterial, will not restart the running of this acceptance period. You hereby are advised to consult with an attorney prior to signing this Agreement. 

12. Right to Revoke and Rescind. You are hereby informed of your right to revoke your release of claims, insofar as it extends to
potential claims under the Age Discrimination in Employment Act, by informing EnteroMedics of your intent to revoke your release of claims within 7 calendar days following your signing of this Agreement. You are also informed of your right to
rescind your release of claims, insofar as it extends to potential claims under the Minnesota Human Rights Act, by delivering a written rescission to EnteroMedics within 15 calendar days after your signing of this Agreement. You understand that any
such revocation or rescission must be made in writing and delivered by hand or by certified mail, return receipt requested, postmarked on or before the last day within the applicable revocation period to: Greg Lea, Senior Vice President, CFO and
COO, EnteroMedics, Inc., 2800 Patton Road, St. Paul, MN 55113. 
 If you exercise your right to revoke or rescind this Agreement, EnteroMedics may, at its
option, either nullify this Agreement in its entirety, or keep it in effect in all respects other than as to that portion of your release of claims that you have revoked or rescinded. You agree and understand that if EnteroMedics chooses to nullify
the Agreement in its entirety, EnteroMedics will have no obligations under this Agreement to you or to others whose rights derive from you. 

13. Entire Agreement. This Agreement, as well as the exhibits hereto and any agreements referenced herein, is the final, complete and
exclusive agreement of the parties and sets forth the entire agreement between EnteroMedics and you with respect to your employment by EnteroMedics, and there are no undertakings, covenants or commitments other than as set forth herein. The
Agreement may not be altered or amended, except by a writing executed by you and a member of the Board. Except as otherwise indicated, this Agreement supersedes, terminates, replaces and supplants any and all prior understandings or agreements
between the parties relating in any way to you hiring or employment by EnteroMedics. 

  
 4 

 14. Governing Law. The laws of the State of Minnesota will govern the validity,
construction and performance of this Agreement, without regard to the conflict of law provisions of any other jurisdictions. If any part of this Agreement is construed to be in violation of any law, such part shall be modified to achieve the
objective of the parties to the fullest extent permitted and the balance of this Agreement shall remain in full force and effect. If such modification is not possible, said provision will be deemed severable from the remaining provisions of this
Agreement and the balance of this Agreement shall remain in full force and effect. 
 15. Remedies. To the extent that the
EnteroMedics wishes to pursue remedies against you under Section 7.1 of the Employment Agreement, you and EnteroMedics agree that such action shall be venued in Minnesota District Court, Hennepin County. For any other dispute, you and
EnteroMedics irrevocably consent that any litigation commenced or arising in connection with the interpretation or enforcement of this Agreement that has not been settled through negotiation within a period of thirty (30) days after the date on
which either party shall first have notified the other party in writing of the existence of a dispute shall be settled by final and binding arbitration under the then-applicable Employment Arbitration Rules of the American Arbitration Association
(“AAA”). Any such arbitration shall be conducted by one (1) neutral arbitrator appointed by mutual agreement of the parties or, failing such agreement, in accordance with the AAA Rules. The arbitrator shall be an experienced attorney
with a background in employment law. Any arbitration shall be conducted in Minneapolis, Minnesota. An arbitration award may be enforced in any court of competent jurisdiction. Notwithstanding any contrary provision in the AAA Rules, the following
additional procedures and rules shall apply to any such arbitration: 
  

	 	(A)	Each party shall have the right to request from the arbitrator, and the arbitrator shall order upon good cause shown, reasonable and limited pre-hearing discovery, including:
(i) exchange of witness lists, (ii) no more than two (2) depositions under oath of named witnesses at a mutually convenient location (neither deposition to exceed seven (7) hours), (iii) written interrogatories (no more than
twenty-five (25) in number), and (iv) document requests (no more than twenty-five (25) in number, including subparts); 

  

	 	(B)	Upon conclusion of the pre-hearing discovery, the arbitrator shall promptly hold a hearing upon the evidence to be adduced by the parties and shall promptly render a written opinion and award; 

 

	 	(C)	The arbitrator may award damages or injunctive relief consistent with the terms of this Agreement but may not award or assess punitive damages against either party; and 

 

	 	(D)	Each party shall bear his or its own costs and expenses of the arbitration and one-half (1/2) of the fees and costs of the arbitrator, subject to the power of the arbitrator, in his or her sole discretion, to award
all such reasonable costs, expenses and attorneys’ fees to the prevailing party. 

  
 5 

 16. No Admission. Nothing in this Agreement is intended to be, and nothing will be deemed
to be, an admission of liability by EnteroMedics or you that either party has violated any state or federal statute, local ordinance or principle of common law, or that either party has engaged in any wrongdoing. 

17. Waiver. No waiver of any provision of this Agreement shall be binding unless executed in writing by the party making the waiver.
The waiver by either party of a breach by the other party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach. 

IN WITNESS WHEREOF, the parties have duly executed this Agreement on the dates set forth below to be effective as of the date shown below. 

I acknowledge and agree that I have read this Agreement in its entirety and that I agree to the conditions and obligations set forth herein. Further, I
agree that I have had adequate time to consider the terms of this Agreement and that I am voluntarily entering into this Agreement with a full understanding of its meaning. I understand that I am hereby advised to consult with an attorney before
signing this Agreement. 
  

											
		 		 		 	
					
	Dated:	 	  
	 		 		 	 
		 		 		 		 	Scott P. Youngstrom
					
		 		 		 		 	ENTEROMEDICS INC.
						
	Dated:	 	  
	 		 		 	By	 	  

						
		 		 		 		 	Its	 	  

  
 6EX-4.1

 Exhibit 4.1 

CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
 WARRANT AND REGISTRATION RIGHTS
AGREEMENT 
 by and among 

ARRIS INTERNATIONAL PLC, 

CHARTER COMMUNICATIONS OPERATING, LLC 

and 
 ANY OTHER HOLDERS
OF WARRANTS ISSUED HEREUNDER 
 Dated as of September 30, 2016 

 
  

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 WARRANT AND REGISTRATION RIGHTS AGREEMENT 

AGREEMENT dated as of September 30, 2016 (the “Issuance Date”), by and among ARRIS INTERNATIONAL PLC, a company
incorporated under the laws of England and Wales (the “Company”), CHARTER COMMUNICATIONS OPERATING, LLC, a limited liability company organized under the laws of the State of Delaware, U.S.A. (“Charter”), and any
other Holders of Warrants issued hereunder. 
 W I T N E S S E T H: 

WHEREAS, General Instrument Corporation, a wholly-owned subsidiary of the Company, and Charter Communications Operating, LLC (“Charter
Communications”) have entered into that certain Master Purchase Agreement having an effective date of May 12, 2012, as amended (as the same shall be further amended from time to time, the “May 2012 MPA”); and 

WHEREAS, ARRIS Solutions, Inc., a wholly-owned subsidiary of the Company, and Charter Communications have entered into that certain Master
Purchase Agreement having an effective date of January 1, 2012, as amended (as the same shall be further amended from time to time, the “January 2012 MPA” and, collectively with the May 2012 MPA and any agreement that
supersedes or replaces the January 2012 MPA and/or the May 2012 MPA, the “MPA”); and 
 WHEREAS, the Company is issuing and
delivering warrant certificates in the form attached as Exhibit A hereto (the “Warrant Certificates”) evidencing Warrants to purchase up to 6,000,000 Ordinary Shares, subject to adjustment as provided herein, as an incentive to
Charter and its Affiliates to purchase certain Goods from the Company pursuant to the MPA. 
 NOW, THEREFORE, in consideration of the
foregoing, the Company, Charter and each other Holder hereby agree as follows: 
 ARTICLE I 

Definitions 
 All
capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the MPA. As used in this Agreement, the following terms shall have the following respective meanings: 

“Affiliate” means, with respect to any Person, a Person that directly or indirectly controls, is controlled by or is under
direct or indirect common control with such Person. For purposes of this definition, “control” when used with respect to any Person means the power to direct the management and policies of such Person, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise, and the terms “controlling” and “controlled” have meanings correlative to the foregoing. 

  
 1 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 “Attempted Exercise” has the meaning set forth in Section 9.03(b). 

“Board” means the board of directors of the Company. 

“Business Day” means any day that is not a day on which banking institutions are authorized or required to be closed in the
City of London or the City of New York. 
 “Change of Control” means the occurrence of any of the following events: 

(a) the acquisition by any Person, including any syndicate or group deemed to be a “person” under Section 13(d)(3) of the
Exchange Act, of beneficial ownership (determined in accordance with Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, through a purchase, merger or other acquisition transaction or series of purchases, mergers or other
acquisition transactions, of shares of the Company (i) entitling that person to exercise 50% or more of the total voting rights of all shares of the Company entitled to vote generally in elections of directors or (ii) comprising 50% or
more of the total equity value of the Company, other than any acquisition by the Company, any of its subsidiaries or any of its employee benefit plans; or 

(b) the consolidation or merger of the Company with or into any other Person, any merger of another Person into the Company, or any
conveyance, transfer, sale, lease or other disposition of all or substantially all of the Company’s properties and assets to another Person, other than any transaction pursuant to which the holders of the Company’s shares entitled to vote
generally in elections of directors immediately prior to such transaction have the entitlement to exercise, directly or indirectly, 50% or more of the total voting rights of all shares of the Company entitled to vote generally in elections of
directors of the continuing or surviving Person immediately after giving effect to such transaction in substantially the same proportions to one another as such holders of the Company’s shares held immediately before giving effect to such
transaction. 
 “Company” has the meaning set forth in the preamble to this Agreement, and its successors and assigns. 

“Company Financial Statements” has the meaning set forth in Section 8.02(f). 

“Demand Registration” has the meaning set forth in Section 4.01(a). 

“Excess Tender Amount” has the meaning set forth in Section 5.04. 

  
 2 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 “Exchange Act” means the United States Securities Exchange Act of 1934, as
amended, together with the rules and regulations promulgated thereunder. 
 “Ex-date” means, in the case of any dividend or
distribution by the Company with respect to the Underlying Stock, the date on which the Underlying Stock first trades without the right to receive such dividend or distribution on the principal national securities exchange or quotation system on
which the Underlying Stock is listed or admitted to trading. 
 “Exercise Date” has the meaning set forth in
Section 4(a). 
 “Exercise Price” has the meaning set forth in Section 3.01. 

“Expenses” means all fees and expenses incurred by the Company and the Holders in effecting any registration pursuant to this
Agreement, including all registration and filing fees, printing expenses, fees and expenses in connection with listing the Registrable Securities on any securities exchange or quotation system, reasonable fees and disbursements of one counsel
selected by all Holders of Registrable Securities included in such registration, Blue Sky fees and expenses, fees and expenses of the Company’s counsel and fees and expenses of the Company’s independent accountants in connection with any
regular or special reviews or audits incident to or required by any such registration, but excluding all underwriting discounts and selling commissions applicable to the sale of the applicable Registrable Securities. 

“Expiration Date” means September 30, 2023, subject to extension pursuant to Section 9.03(a). 

“Fair Market Value” means, as of any given date: 

(a) in the case of any equity interest (including the Underlying Stock): (i) if the class and series of such equity interest is as of
such date, and has been for a period of at least four months prior to such date, listed on the New York Stock Exchange or the NASDAQ Stock Market, the average daily volume-weighted average price per share of such equity interest for the ten
(10) consecutive trading days ending on the trading day immediately preceding such date (as reported by Bloomberg L.P., without regard to pre-open or after hours trading outside of any regular trading sessions for any such scheduled trading day
on such trading day), and (ii) if clause (i) is not applicable, the price, as determined by an Independent Financial Expert, at which such equity interest would be sold in an arm’s-length transaction for cash between a willing seller
and a willing and able buyer, both having full knowledge of the relevant facts and neither of which is under any compulsion to buy or sell, taking into account all relevant factors using one or more valuation methods that the Independent Financial
Expert in its best professional judgment determines to be most appropriate but without regard for control premiums or minority or illiquidity discounts; 

  
 3 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 (b) in the case of any asset other than an equity interest or cash, the price, as determined
by an Independent Financial Expert, at which such asset would be sold in an arm’s-length transaction for cash between a willing seller and a willing and able buyer, both having full knowledge of the relevant facts and neither of which is under
any compulsion to buy or sell, taking into account all relevant factors and using one or more valuation methods that the Independent Financial Expert in its best professional judgment determines to be most appropriate; and 

(c) in the case of cash, the amount thereof. 

“Holder” means Charter, and its successors and permitted assigns and transferees of any Warrants in accordance with this
Agreement. 
 “including” means “including, without limitation”. 

“Independent Financial Expert” means a nationally recognized investment banking firm selected by the Company and approved by
the Holder (each acting within their reasonable discretion), which firm does not have, and has not had for a period of at least 24 months prior to the date of its selection, a material financial interest in, or other material economic relationship
with, the Company or any of its Affiliates. 
 “Issuance Date” has the meaning set forth in the preamble to this Agreement.

 “Loss” and “Losses” have the meanings set forth in Section 4.07(a). 

“Material Adverse Effect” means a material adverse effect on the business, assets, liabilities, financial condition, property
or results of operations of the Company and its subsidiaries taken as a whole; provided, however, that none of the following, in and of itself or themselves, shall constitute a Material Adverse Effect: (a) changes in the economy
or financial markets generally in the United States or other countries in which the Company or its subsidiaries conduct operations; (b) changes in United States generally accepted accounting principles or in any law applicable to the Company or
its subsidiaries or the enforcement or interpretation thereof; (c) any regulatory, legislative or political conditions or securities, credit, financial or other capital markets conditions, in each case in the United States or any other
countries in which the Company or its subsidiaries conduct operations; (d) any geopolitical conditions, the outbreak, continuation or escalation of hostilities, any acts of war (whether or not declared), sabotage, terrorism or military actions,
or any large scale public health epidemics, weather conditions or other force majeure events; (e) any changes that are the result of factors generally affecting the industry or industries in which the Company and its subsidiaries operate;
(f) any failure by the Company to meet any estimates, projections or expectations of revenues, earnings or other financial performance or results of operations for any period, or any failure by the Company to meet its internal budgets, plans or
forecasts of its revenues, earnings or other financial performance or results of 

  
 4 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
operations; (g) a decline in the price or trading volume of the Ordinary Shares on the NASDAQ Stock Market; or (h) any reduction in the credit rating of the Company or any of its
subsidiaries, except (i) in the case of clauses (a) through (e) (inclusive), to the extent the Company and its subsidiaries taken as a whole are materially and disproportionally affected thereby, and (ii) in the case of clauses
(f) through (h) (inclusive), that such exception shall not prevent or otherwise affect a determination that any change, effect, circumstance or development underlying the failure, decline or reduction described in such exception that is
not otherwise excluded pursuant to this definition has resulted in, or contributed to, a Material Adverse Effect. 
 “Maximum
Aggregate Ownership Amount” has the meaning set forth in Section 9.03(b). 
 “Maximum Aggregate Voting
Amount” has the meaning set forth in Section 9.03(b). 
 “Maximum Number of Securities” has the meaning set
forth in Section 4.01(e). 
 “MPA” has the meaning set forth in the recitals to this Agreement. 

“Net Cash Settlement” has the meaning set forth in Section 3.04(d). 

“Net Share Settlement” has the meaning set forth in Section 3.04(c). 

“Ordinary Shares” means the ordinary shares, nominal value £0.01 per share, in the capital of the Company. 

“Person” means any individual, corporation, limited liability company, partnership, joint venture, association, joint stock
company, trust, unincorporated organization or government or any agency or political subdivision thereof. 
 “Physical
Delivery” has the meaning set forth in Section 3.04(b). 
 “Piggyback Registration” has the meaning set forth
in Section 4.02(a). 
 “Premium Per Pro Forma Share” has the meaning set forth in Section 5.04. 

“Prospectus” means the prospectus included in any Registration Statement, as amended or supplemented by any prospectus
supplement with respect to the terms of the offering of any of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to the prospectus, including post-effective amendments and all material
incorporated by reference in such prospectus. 
 “Recapitalization Event” has the meaning set forth in
Section 5.05(a). 

  
 5 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 “register”, “registered”, and
“registration” shall refer to a registration effected by preparing and (a) filing a Registration Statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration of or
automatic effectiveness of such Registration Statement, or (b) filing a Prospectus and/or prospectus supplement in respect of an appropriate effective Registration Statement on Form S-3. 

“Registrable Securities” means (a) all Underlying Stock issued or issuable upon exercise of the Warrants and
(b) any securities issued or issuable with respect to the Underlying Stock, including as a result of a dividend or distribution, stock split or combination, Recapitalization Event or Reorganization Event. Registrable Securities shall continue
to be Registrable Securities (whether they continue to be held by the Holder or they are sold to other Persons) until (i) they are sold pursuant to an effective Registration Statement under the Securities Act; (ii) they are sold pursuant
to Rule 144; or (iii) they shall have otherwise been transferred and new securities not subject to transfer restrictions under any United States federal or state securities laws and not bearing any legend restricting further transfer shall
have been delivered by the Company, all applicable holding periods shall have expired, and no other applicable and legally binding restriction on transfer by the Holder thereof shall exist under any United States federal or state securities laws.

 “Registration Rights” means the rights of Holders set forth in Article IV to have shares of Registrable Securities
registered under the Securities Act for sale under one or more effective Registration Statements. 
 “Registrar” means the
registrar of the Company from time to time, being Computershare Inc., 250 Royall Street, Canton, Massachusetts 02021 at the Issuance Date. 

“Registration Statement” means any registration statement filed by the Company under the Securities Act pursuant to the
Registration Rights, including the Prospectus, any amendments and supplements to such registration statement, including post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement. 

“Reorganization Event” has the meaning set forth in Section 5.05(a). 

“Rule 144”, “Rule 144A” and “Rule 415” mean, in each case, such rule promulgated
under the Securities Act (or any successor provision), as such rules may be amended from time to time. 
 “SEC” means the
United States Securities and Exchange Commission. 
 “SEC Documents” has the meaning set forth in Section 8.02(f).

  
 6 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 “Securities Act” means the United States Securities Act of 1933, as amended,
together with the rules and regulations promulgated thereunder. 
 “Specified Dividend” means any cash dividend by the
Company to all holders of Underlying Stock with respect to which (i) if the Underlying Stock is as of such date, and has been for a period of at least four months prior to such date, listed on the New York Stock Exchange or the NASDAQ Stock
Market, the daily volume-weighted average price per share of the Underlying Stock for the last trading day before the Ex-date is at least five percent (5%) greater than the daily volume-weighted average price per share of the Underlying Stock
for the Ex-date (in each case as reported by Bloomberg L.P., without regard to pre-open or after hours trading outside of any regular trading sessions for any such scheduled trading day on such trading day); or (ii) if clause (i) is not
applicable, the per share amount of such cash dividend equals or exceeds five percent (5%) of the Fair Market Value of a share of Underlying Stock. 

“Subscription Notice” has the meaning set forth in Section 3.04(a). 

“Underlying Stock” means the class and series of equity interests issuable or issued upon the exercise of the Warrants from
time to time, being Ordinary Shares as of the Issuance Date. 
 “Warrant” means a warrant issued by the Company from time
to time pursuant to this Agreement and evidenced by a Warrant Certificate. 
 “Warrant Certificate” has the meaning set
forth in the recitals to this Agreement. 
 ARTICLE II 

Original Issue of Warrants 

SECTION 2.01. Form of Warrant Certificates. The Warrant Certificates shall be in registered form only and substantially in the form
attached hereto as Exhibit A, shall be dated the date on which signed by the Company and may have such legends and endorsements typed, stamped, printed, lithographed or engraved thereon as provided in Section 3.05 or as may be required to
comply with any applicable law or with any applicable rule or regulation pursuant thereto. The Warrants will not be publicly listed on any exchange and shall only be transferable in accordance with Article III. 

SECTION 2.02. Execution and Delivery of Warrant Certificates. (a) Simultaneously with the execution of this Agreement, the Company
shall execute and deliver to Charter Warrant Certificates evidencing an aggregate of 6,000,000 Warrants entitling the Holder thereof to purchase an aggregate of up to 6,000,000 Ordinary Shares, subject to adjustment as provided herein. 

  
 7 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 (b) From time to time, the Company shall execute and deliver Warrant Certificates in required
denominations to Persons entitled thereto in connection with any exchange or transfer permitted under this Agreement. The Warrant Certificates shall be executed on behalf of the Company by its President, Chief Executive Officer, Chief Financial
Officer, Secretary or Executive Vice President, either manually or by facsimile signature printed thereon. In case any officer of the Company whose signature shall have been placed upon any of the Warrant Certificates shall cease to be such officer
of the Company before issue and delivery thereof, such Warrant Certificates may, nevertheless, be issued and delivered with the same force and effect as though such person had not ceased to be such officer of the Company. 

ARTICLE III 
 Exercise Price;
Exercise of Warrants and Expiration of Warrants 
 SECTION 3.01. Exercise Price. Each Warrant Certificate shall entitle, but
shall not oblige, the Holder thereof, subject to the provisions of this Agreement including the vesting requirements set forth in Annex A, to purchase one Ordinary Share for each Warrant represented thereby, at an exercise price per Ordinary Share
(the “Exercise Price”) set forth on such Warrant Certificate and determined in accordance with Annex A, subject to all adjustments made on or prior to the date of exercise thereof as herein provided. 

SECTION 3.02. Exercise of Warrants. To the extent vested, the Warrants shall be exercisable, in whole or in part, at any time and from
time to time, on any Business Day beginning on the date of vesting and ending on the Expiration Date. A Warrant shall be deemed to vest on, and become exercisable from and after, such date(s) and to the extent specified in Annex A hereto. 

SECTION 3.03. Expiration of Warrants. Any unexercised Warrants shall expire and the rights of the Holders of such Warrants to purchase
Underlying Stock shall terminate at the close of business on the Expiration Date. 
 SECTION 3.04. Method of Exercise. 

(a) In order to exercise a Warrant, the Holder thereof must surrender the Warrant Certificate evidencing such Warrant, together with the form
on the reverse of or attached to the Warrant Certificate duly executed and specifying the amount of Underlying Stock as to which the Warrant Certificate is being exercised (a “Subscription Notice”), to the Company (the date on which
such delivery shall have taken place being referred to as the “Exercise Date”). Each exercise of this Warrant shall be settled through Physical Delivery or Net Share Settlement, as elected by the Holder in its sole discretion and
set forth in the Subscription Notice, which may also include, at the Holder’s sole discretion, a request for a settlement of such exercise through Net Cash Settlement. 

  
 8 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 (b) Subject to Section 3.04(d) (if the Subscription Notice included a request for Net
Cash Settlement) and Section 9.03, if the Holder has elected to settle the exercise of a Warrant through physical delivery of Underlying Stock upon cash payment of the Exercise Price by the Holder (“Physical Delivery”) in
accordance with Section 3.04(a), then (i) within three (3) Business Days following the Exercise Date, the Holder shall deliver to the Company the aggregate Exercise Price for the Underlying Stock specified in the applicable
Subscription Notice by wire transfer of immediately available funds to an account or accounts designated by the Company, and (ii) the Company shall allot and issue to the Holder the Underlying Stock specified in the applicable Subscription
Notice as provided in Section 3.04(f). 
 (c) Subject to Section 3.04(d) (if the Subscription Notice included a request for Net
Cash Settlement) and Section 9.03, if the Holder has elected to settle the exercise of a Warrant through a net, or “cashless”, exercise by using a portion of the Underlying Stock that the Holder otherwise would have received upon such
settlement as payment of the Exercise Price (“Net Share Settlement”) in accordance with Section 3.04(a) and at the time of such exercise the Fair Market Value of the Underlying Stock exceeds the Exercise Price (if the Holder
elects Net Share Settlement but the Fair Market Value of the Underlying Stock is determined not to exceed the Exercise Price, the Holder shall be deemed to have elected Physical Delivery instead), the Company shall allot and issue to the Holder, as
provided in Section 3.04(f), a number of shares of Underlying Stock computed using the following formula: 
  

							
		 	A =   B x (D-C)  
		 	              D
		
		 	Where:
				
		 	A	  	=	  	the number of shares of Underlying Stock to be issued to the Holder
				
		 	B	  	=	  	the number of shares of Underlying Stock specified in the applicable Subscription Notice
				
		 	C	  	=	  	the Exercise Price on the Exercise Date
				
		 	D	  	=	  	the Fair Market Value of the Underlying Stock on the Exercise Date

 (d) If (i) the Holder has requested to settle the exercise of a Warrant through payment of cash by the
Company to the Holder, net of the Exercise Price, in lieu of issuing any Underlying Stock (“Net Cash Settlement”) in accordance with Section 3.04(a), (ii) at the time of such exercise the Fair Market Value of the
Underlying Stock exceeds the Exercise Price, and (iii) the Company agrees, in its sole discretion, to effect such Net Cash Settlement in lieu of the settlement election made by the Holder in the

  
 9 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
Subscription Notice (in which case the Company shall so notify the Holder in writing within two (2) Business Days following the Exercise Date), the Company shall pay to the Holder, by wire
transfer of immediately available funds to an account or accounts designated by the Holder in the Subscription Notice within five (5) Business Days following the Exercise Date, an amount of cash computed using the following formula: 

 

							
		 	A =   B x (D-C)  
		
		 	Where:
				
		 	A	  	=	  	the Net Cash Settlement amount
				
		 	B	  	=	  	the number of shares of Underlying Stock specified in the applicable Subscription Notice
				
		 	C	  	=	  	the Exercise Price on the Exercise Date
				
		 	D	  	=	  	the Fair Market Value of the Underlying Stock on the Exercise Date

 (e) If fewer than all Warrants represented by a Warrant Certificate are exercised, the Holder shall surrender
such Warrant Certificate with the Subscription Notice and the Company shall promptly execute and deliver a new Warrant Certificate of the same tenor and for the number of Warrants that were not exercised to the Person or Persons as may be directed
in writing by the Holder (subject to the terms hereof), and the Company shall register the new Warrant Certificate in the name of such Person or Persons. 

(f) Upon exercise of a Warrant in accordance with the foregoing provisions of this Section 3.04 pursuant to which the Holder has elected
to settle such exercise through Physical Delivery or Net Share Settlement, then, as soon as practicable after such exercise and in any event within three (3) Business Days thereafter (but (x) if the Holder has elected to settle such
exercise through Physical Delivery, subject to the Holder’s payment of the aggregate Exercise Price as contemplated by Section 3.04(b), and (y) if the Holder has requested Net Cash Settlement, subject to the Company’s agreement
to settle such exercise through Net Cash Settlement), the Company shall allot and issue to the Holder the appropriate number of shares of Underlying Stock and instruct the Registrar to issue to the Holder appropriate evidence of ownership of such
shares of Underlying Stock and any cash, securities or other property to which the Holder is entitled, registered or otherwise placed in, or payable to the order of, such name or names as may be directed in writing by the Holder (subject to the
terms hereof), and shall deliver such evidence of ownership and any cash, securities or other property to the Person or Persons entitled to receive the same, together with an amount in cash in lieu of any fraction of a share as provided in
Section 3.04(g) (for the avoidance of doubt, the Company may deliver the Underlying Stock via book entry). Upon delivery of a 

  
 10 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
Subscription Notice, a Holder shall be deemed to own and have all of the rights associated with any Underlying Stock or cash, securities or other property to which it is entitled pursuant to this
Agreement upon the surrender of a Warrant Certificate in accordance with this Agreement. If the Holder shall direct that any Underlying Stock or other securities be registered in a name other than that of the Holder, such direction shall be tendered
in conjunction with a signature guarantee from an eligible guarantor institution participating in a signature guarantee program approved by the Securities Transfer Association. 

(g) No fractional shares shall be issued upon exercise of any Warrant. Instead, the Company shall pay to the Holder, in lieu of issuing any
fractional share, a sum in cash equal to such fraction multiplied by the Fair Market Value of the Underlying Stock as of Exercise Date. 

SECTION 3.05. Transferability of the Warrants. 

(a) At any time after the Issuance Date, any Warrants (whether vested or unvested) may be transferred by the Holder to (i) any Affiliate
of the Holder (provided that, if any such transferee to which any unvested Warrants have been transferred ceases to constitute an Affiliate of the Holder, such transferee shall be required to transfer such unvested Warrants back to the Holder or one
of its other Affiliates) or (ii) any assignee of the Holder’s rights and obligations under the MPA. For the avoidance of doubt, in no event shall any change in control of the Holder (or any transactions in the securities of Charter or any
successor parent company of the Holder) constitute a transfer of the Warrants. 
 (b) Without limiting Section 3.05(a), at any time
after the vesting of any Warrants, such vested Warrants and any Underlying Stock or other securities received by the Holder upon exercise thereof may be transferred by the Holder to any Person, subject to compliance with Section 3.06. 

(c) Promptly following the transfer of any Warrants in accordance herewith, the Holder shall surrender the applicable Warrant Certificate to
the Company, together with written notice of (i) the name, address, telephone number and facsimile number of the transferee and (ii) the number of Warrants so transferred. Promptly following delivery by the Holder of such notice (and in
any event within five (5) Business Days thereafter), the Company shall (A) deliver to the designated transferee one or more new Warrant Certificates in the denominations as set forth in such notice, (B) if applicable, deliver to the
Holder a new Warrant Certificate evidencing the balance of the Warrants not assigned by the Holder, and (C) register such transfer in accordance with Section 6.01. Any Warrants, if properly transferred in compliance with this
Section 3.05, may be exercised by the new Holder without having a new Warrant Certificate issued. 

  
 11 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 (d) Subject to Section 10.04, each Warrant Certificate shall bear the following legend:

 THESE WARRANTS MAY ONLY BE TRANSFERRED IN ACCORDANCE WITH THE TERMS OF THE WARRANT AND REGISTRATION RIGHTS AGREEMENT REFERRED TO BELOW.
NEITHER THESE WARRANTS NOR THE SECURITIES ISSUABLE UPON THE EXERCISE THEREOF HAVE BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS. SUCH WARRANTS AND SECURITIES MAY BE
OFFERED, SOLD OR TRANSFERRED ONLY IN COMPLIANCE WITH THE REQUIREMENTS OF SUCH ACT AND OF ANY APPLICABLE STATE SECURITIES LAWS AND SUBJECT TO THE PROVISIONS OF THE WARRANT AND REGISTRATION RIGHTS AGREEMENT DATED AS OF SEPTEMBER 30, 2016, BY AND AMONG
ARRIS INTERNATIONAL PLC (THE “COMPANY”), CHARTER AND ANY OTHER HOLDERS OF WARRANTS ISSUED THEREUNDER. A COPY OF SUCH WARRANT AND REGISTRATION RIGHTS AGREEMENT IS AVAILABLE AT THE OFFICES OF THE COMPANY. 

SECTION 3.06. Compliance with the Securities Act. 

(a) Neither the Warrants nor the Underlying Stock have been registered under the Securities Act or qualified under any applicable state
securities laws and, unless so registered (including pursuant to a registration of Registrable Securities effected in accordance with Article IV), may not be sold, transferred or otherwise disposed of unless an exemption from such registration is
available, including pursuant to Rule 144 or to a transferee that is an “accredited investor” or a “qualified institutional buyer” (as such terms are defined in Regulation D and Rule 144A, respectively, under the Securities
Act). In the case of a sale, transfer or other disposition of the Warrants or the Underlying Stock other than in open market sales pursuant to Rule 144 or in a registered offering, each of the following conditions must be satisfied: 

(i) with respect to a sale, transfer or other disposition to an accredited investor that is not an institution, such transferee
provides certification establishing to the reasonable satisfaction of the Company that it is an accredited investor; 
 (ii)
such transferee represents that (A) it is acquiring the Warrants or the Underlying Stock, as applicable, for its own account and not with a view to, or for offer or sale in connection with, any distribution

  
 12 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
thereof (within the meaning of the Securities Act) that would be in violation of the securities laws of the United States or any applicable state thereof and (B) it has no intention to
influence the management of the Company; and 
 (iii) such transferee agrees to be bound by the provisions of this
Section 3.06 with respect to any subsequent sale, transfer or other disposition of the Warrants or Underlying Stock, as applicable. 

(b) Subject to Section 10.04, all certificates for Underlying Stock issued pursuant to the exercise of the Warrants shall bear the
following legend: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933,
AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS. SUCH SHARES MAY BE OFFERED, SOLD OR TRANSFERRED ONLY IN COMPLIANCE WITH THE REQUIREMENTS OF SUCH ACT AND OF ANY APPLICABLE STATE SECURITIES LAWS AND SUBJECT TO THE PROVISIONS OF THE
WARRANT AND REGISTRATION RIGHTS AGREEMENT DATED AS OF SEPTEMBER 30, 2016, BY AND AMONG ARRIS INTERNATIONAL PLC (THE “COMPANY”), CHARTER AND ANY OTHER HOLDERS OF WARRANTS ISSUED THEREUNDER. A COPY OF SUCH WARRANT AND REGISTRATION RIGHTS
AGREEMENT IS AVAILABLE AT THE OFFICES OF THE COMPANY. 
 ARTICLE IV 

Registration Rights 

SECTION 4.01. Demand Registration Rights. 

(a) At any time one or more Holders may make a written request to the Company for registration of all or any part of the Registrable
Securities held by such requesting Holder(s) (a “Demand Registration”); provided, however, that the Company shall not be required to effect more than one (1) Demand Registration pursuant to this
Section 4.01(a). Each request for a Demand Registration shall specify the aggregate amount of Registrable Securities to be registered and the intended methods of disposition thereof. Within five (5) Business Days following receipt of any
request for a Demand Registration, the Company shall deliver written notice of such request to all other Holders of Registrable Securities. Thereafter, the Company shall include in such Demand Registration any additional Registrable Securities which
the Holder or Holders thereof have requested in writing be included in such Demand Registration, provided that all 

  
 13 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
requests therefor have been received by the Company within ten (10) Business Days of the Company’s having sent the applicable notice to such Holder or Holders. All such requests shall
specify the aggregate amount of Registrable Securities to be registered and the intended method of distribution of the same. The Company shall not include in any Demand Registration any securities that are not Registrable Securities without the
prior written consent of the Holder(s) requesting such Demand Registration, which consent shall not be unreasonably withheld or delayed. 

(b) As promptly as practicable following receipt of a request for a Demand Registration, but in no event prior to the earlier of (i) the
filing by the Company of its Form 10-K for the year ending December 31, 2016 and (ii) March 31, 2017, the Company shall file a Registration Statement relating to such Demand Registration and shall use its reasonable best efforts to
cause such Registration Statement to be declared effective under the Securities Act. The Company may postpone for up to 60 consecutive days the filing or effectiveness of a Registration Statement for a Demand Registration if the Board determines in
its reasonable good faith judgment that such Demand Registration would (x) materially interfere with a significant acquisition, corporate reorganization or other similar transaction involving the Company or its subsidiaries; or (y) require
premature disclosure of material nonpublic information that the Company has a bona fide business purpose for preserving as confidential; provided, however, that the Company may delay a Demand Registration hereunder only twice in a
period of twelve (12) consecutive months. 
 (c) A Holder may withdraw its Registrable Securities from a Demand Registration prior to
the effectiveness of the Registration Statement filed with respect to such Demand Registration. If all Holders that requested the Demand Registration do so, the Company shall be entitled to cease all efforts to secure registration, in which event
the Holder(s) who requested such registration shall pay or reimburse the Company for all of the reasonable out-of-pocket fees and expenses incurred by the Company in connection with the withdrawn registration, unless (i) the withdrawal is based
on the reasonable determination of the Holder(s) who requested such registration that there has been, since the date of such request, a Material Adverse Effect or (ii) such Holder(s) agree to forfeit their one (1) Demand Registration. 

(d) If the Holder(s) that requested the Demand Registration so elect, such offering shall be in the form of an underwritten registration. The
Holder(s) that requested the Demand Registration shall have the right to select the managing underwriters for the offering, which selection shall be subject to the consent of the Company, which consent shall not be unreasonably withheld or delayed.

 (e) If a Demand Registration is initiated as an underwritten registration, and the managing underwriters advise the Company and the
Holders that in their reasonable opinion the number of Registrable Securities and other securities proposed to be included in such registration exceeds the number of Registrable Securities 

  
 14 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
and other securities that can be sold in such underwritten offering without materially delaying or jeopardizing the success of the offering (including the offering price per share) (such maximum
number of shares, the “Maximum Number of Securities”), then the Company shall include in such registration: (i) first, the number of Registrable Securities requested to be included therein by the Holder(s) requesting such
registration, allocated pro rata among such Holders on the basis of the number of Registrable Securities requested to be included therein by such Holders or as such Holders and the Company may otherwise agree; (ii) second, the number of
securities requested to be included therein by other security holders; and (iii) third, the number of securities that the Company proposes to sell. 

(f) Any Demand Registration shall be on such appropriate registration form of the SEC (i) as shall be selected by the Company and
reasonably acceptable to the Holder(s) that requested the Demand Registration and (ii) as shall permit the disposition of the Registrable Securities in accordance with the intended method or methods of disposition specified in the applicable
Holders’ requests for such registration. Notwithstanding the foregoing, if, pursuant to a Demand Registration, (A) the Company proposes to effect this registration by filing a Registration Statement on Form S-3 or Form F-3 (or any
successor or similar short-form registration statement), (B) such registration is to be underwritten and (C) the managing underwriters shall advise the Company in writing that, in its or their opinion, the use of another form of
registration statement (or the inclusion, rather than the incorporation by reference, of information in the Prospectus related to a Registration Statement on Form S-3 or Form F-3 (or other short-form registration statement)) is of material
importance to the success of such proposed offering, then such registration shall be effected on such other form (or such information shall be so included in such Prospectus). 

SECTION 4.02. Piggyback Registration Rights. 

(a) If at any time the Company has registered or has determined to register any of its equity securities for its own account or for the
account of other security holders of the Company on any registration form (other than Form S-4 or S-8) which permits the inclusion of the Registrable Securities (a “Piggyback Registration”), the Company will give the Holders written
notice thereof promptly (but in no event less than 15 Business Days prior to the anticipated filing date) and shall include in such registration all Registrable Securities requested to be included therein pursuant to the written request of one
or more Holders received within 10 Business Days after delivery of the Company’s notice. 
 (b) If the offering pursuant to a
Piggyback Registration is to be in the form of an underwritten registration, then each Holder making a request for its Registrable Securities to be included therein must, and the Company shall make such arrangements with the underwriters so that
each such Holder may, participate in such underwritten registration on the same terms as the Company and other Persons selling 

  
 15 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
securities in such Piggyback Registration. If any Piggyback Registration is a primary or secondary underwritten offering, the Company shall have the right to select, in its sole discretion, the
managing underwriter or underwriters to administer any such offering. If the offering pursuant to such registration is to be on any other basis, then each Holder making a request for a Piggyback Registration pursuant to Section 4.02(a) must
participate in such offering on such basis. 
 (c) A Holder may withdraw all or part of its Registrable Securities from a Piggyback
Registration at any time. For the avoidance of doubt, if a Holder decides not to include all of its Registrable Securities in any Registration Statement hereafter filed by the Company, such Holder shall nevertheless continue to have the right to
include any Registrable Securities in any subsequent Registration Statement as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. 

(d) If a Piggyback Registration is initiated as a primary underwritten offering on behalf of the Company, and the managing underwriters advise
the Company and the Holders that in their reasonable opinion the number of Registrable Securities and other securities proposed to be included in such registration exceeds the Maximum Number of Securities, the Company shall include in such
registration: (i) first, the number of securities that the Company proposes to sell; (ii) second, the number of Registrable Securities and other securities requested to be included therein by Holders who have provided notice in accordance
with Section 4.02(a) and other security holders that have, and have duly exercised, contractual registration rights comparable to those set forth in this Agreement, allocated pro rata among all such Holders and other security holders on the
basis of the number of Registrable Securities and other securities requested to be included therein by all such Holders and other security holders or as such Holders and other security holders and the Company may otherwise agree; and
(iii) third, the number of securities requested to be included therein by other security holders. 
 (e) If a Piggyback Registration is
initiated as an underwritten registration on behalf of a holder of securities other than the Holders, and the managing underwriters advise the Company and the Holders that in their reasonable opinion the number of Registrable Securities and other
securities proposed to be included in such registration exceeds the Maximum Number of Securities, then the Company shall include in such registration: (i) first, the number of securities requested to be included therein by the holder(s)
requesting such registration; (ii) second, the number of Registrable Securities and other securities requested to be included therein by Holders who have provided notice in accordance with Section 4.02(a) and other security holders that
have, and have duly exercised, contractual registration rights comparable to those set forth in this Agreement, allocated pro rata among all such Holders and other security holders on the basis of the number of Registrable Securities and other
securities requested to be included therein by all such Holders and other security holders or as such Holders and other security holders and the Company may otherwise agree; (iii) third, the number of securities requested to be included therein
by other security holders; and (iv) fourth, the number of securities that the Company proposes to sell. 

  
 16 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 SECTION 4.03. Expenses of Registration and Selling. All Expenses incurred in
connection with any registration, qualification or compliance hereunder, other than any underwriting discount or selling commission applicable to the sale by a Holder, shall be borne by the Company. 

SECTION 4.04. Obligations of the Company. Whenever required to effect the registration of any Registrable Securities, the Company
shall, as expeditiously as reasonably practicable, subject to the other provisions of this Article IV: 
 (a) Prepare and file with the
SEC a Registration Statement with respect to a proposed offering of Registrable Securities and use commercially reasonable efforts to have such Registration Statement declared effective as promptly as practicable. 

(b) Prepare and file with the SEC such amendments and supplements to the applicable Registration Statement and the Prospectus or prospectus
supplement used in connection with such Registration Statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities covered by such Registration Statement. 

(c) Furnish to the selling Holder or Holders and any underwriters such number of copies of the applicable Registration Statement and each such
amendment and supplement thereto (including in each case all exhibits) and of a Prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in
order to facilitate the disposition of Registrable Securities owned or to be distributed by them. 
 (d) Use commercially reasonable efforts
to register and qualify the securities covered by such Registration Statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the selling Holder or Holders or any managing underwriter(s), to
keep such registration or qualification in effect for so long as such Registration Statement remains in effect, and to take any other action which may be reasonably necessary to enable such selling Holder or Holders to consummate the disposition in
such jurisdictions of the securities owned by such selling Holder or Holders; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business, to file a general
consent to service of process or become subject to taxation in any such states or jurisdictions. 
 (e) Notify the selling Holder or Holders
at any time when a Registration Statement or a Prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the applicable Registration Statement or Prospectus, as then in
effect, contains an untrue statement of a 

  
 17 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein (in the case of such Prospectus, in the light of the circumstances under
which such statements were made) not misleading. 
 (f) Give written notice to the selling Holder or Holders: 

(i) when any Registration Statement has been filed with the SEC and when such Registration Statement or any post-effective
amendment thereto has become effective; 
 (ii) of any request by the SEC or any other U.S. federal or state governmental
authority for amendments or supplements to any Registration Statement or the Prospectus included therein or for additional information; 

(iii) of the issuance by the SEC or any other U.S. federal or state governmental authority of any stop order suspending the
effectiveness of any Registration Statement or the initiation of any proceedings for that purpose or any order preventing or suspecting the use of any Prospectus; 

(iv) of the receipt by the Company or its legal counsel of any notification with respect to the suspension of the qualification
of the Registrable Securities for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and 

(v) of the happening of any event that requires the Company to make changes in any effective Registration Statement or
Prospectus in order to make the statements therein not misleading (in the case of the Prospectus, in the light of the circumstances under which such statements were made) (which notice shall be accompanied by an instruction to suspend the use of the
Prospectus until the requisite changes have been made). 
 (g) Use commercially reasonable efforts to prevent the issuance or obtain the
withdrawal of any order suspending the effectiveness of any Registration Statement or Prospectus referred to in Section 4.05(f)(iii) at the earliest practicable time. 

(h) Upon the occurrence of any event contemplated by Sections 4.04(e) and 4.05(f)(v), promptly prepare a post-effective amendment to such
Registration Statement or a supplement to the related Prospectus or file any other required document so that, as thereafter delivered to the selling Holder or Holders and any underwriters, the Prospectus will not contain an untrue statement of a
material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

  
 18 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 (i) Incorporate in a Prospectus supplement or post-effective amendment to the applicable
Registration Statement such information as the Holder or Holders agree should be included therein relating to the plan of distribution with respect to such Registrable Securities, and make all required filings of such Prospectus supplement or
post-effective amendment after being notified of the matters to be incorporated in such Prospectus supplement or post-effective amendment. 

(j) Comply in all material respects with the provisions of the Securities Act with respect to the sale of all Registrable Securities covered
by such Registration Statement during the applicable period in accordance with the intended method or methods of distribution by the Holder or Holders thereof. 

(k) Use commercially reasonable efforts to procure the cooperation of the Registrar in settling any offering or sale of Registrable
Securities, including with respect to the transfer of physical stock certificates into book-entry form in accordance with any procedures reasonably requested by the selling Holder or Holders or any managing underwriter(s). 

(l) Enter into an underwriting agreement in form, scope and substance as is customarily entered into for similar underwritten offerings of
equity securities by similar companies and take all such other actions reasonably requested by the selling Holder or Holders or by the managing underwriter(s), if any, to expedite or facilitate the underwritten disposition of such Registrable
Securities, and in connection therewith (i) make such representations and warranties to the selling Holder or Holders and the managing underwriter(s), if any, with respect to the business of the Company and its subsidiaries, and the
Registration Statement, Prospectus and documents, if any, incorporated or deemed to be incorporated by reference therein, in each case, in form, substance and scope as are customarily made by the issuer in similar underwritten offerings of equity
securities by similar companies, and, if true, confirm the same if and when requested; (ii) use commercially reasonable efforts to furnish the underwriter(s) with opinions of counsel to the Company, addressed to the managing underwriter(s), if
any, covering the matters customarily covered in the opinions requested in similar underwritten offerings of equity securities by similar companies; (iii) use commercially reasonable efforts to obtain “cold comfort” letters from the
independent certified public accountants of the Company (and, if necessary, any other independent certified public accountants of any business acquired by the Company for which financial statements and financial data are included in the Registration
Statement) who have certified the financial statements included in such Registration Statement, addressed to each of the managing underwriter(s), if any, such letters to be in customary form and covering matters of the type customarily covered in
“cold comfort” letters in connection with similar underwritten offerings of equity securities by similar companies; (iv) if an underwriting agreement is entered into, the same shall contain indemnification provisions and procedures
customary in similar underwritten offerings of equity securities by similar companies and consistent with the provisions of Section 4.07 hereof; and (v) deliver such 

  
 19 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
documents and certificates as may be reasonably requested by the selling Holder or Holders, their counsel and the managing underwriter(s), if any, to evidence the continued validity of the
representations and warranties made pursuant to clause (i) above and to evidence compliance with any customary conditions contained in the underwriting agreement or other agreement entered into by the Company. 

(m) Make available for inspection by a single representative of the selling Holder or Holders and the managing underwriter(s), if any, and
their respective attorneys or accountants, at the offices where normally kept, during reasonable business hours, financial and other records, pertinent corporate documents and properties of the Company, and cause the officers, directors and
employees of the Company to supply all information in each case reasonably requested by any such representative, managing underwriter(s), attorney or accountant in connection with such Registration Statement. 

(n) (i) Use commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed on the
national securities exchange or national market interdealer quotation system on which the Underlying Stock is then listed, and enter into such customary agreements, including a supplemental listing application and indemnification agreement in
customary form; provided, however, that the applicable listing requirements are satisfied, and (ii) provide a registrar for such Registrable Securities covered by such Registration Statement no later than the effective date of
such Registration Statement. The Company shall bear the cost of all reasonable expenses associated with any listing. 
 (o) Make reasonably
available senior executives of the Company to participate in “road show” and other marketing presentations from time to time as reasonably requested by the managing underwriter(s). 

SECTION 4.05. Suspension of Sales. Upon receipt of written notice from the Company in accordance with Sections 4.04(e) and 4.04(f)(v)
to suspend the use of a Prospectus until the requisite changes to the Registration Statement or Prospectus have been made, the selling Holder or Holders shall forthwith suspend use of such Prospectus until the selling Holder or Holders have received
copies of a supplemented or amended Prospectus or prospectus supplement, or until the selling Holder or Holders are advised in writing by the Company that the use of the Prospectus and, if applicable, prospectus supplement may be resumed. If so
directed by the Company, the selling Holder or Holders shall use commercially reasonable efforts to deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in the selling Holder’s or
Holders’ possession, of the Prospectus and, if applicable, prospectus supplement covering such Registrable Securities current at the time of receipt of such suspension notice. 

SECTION 4.06. Furnishing Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant
to Section 4.04 that the 

  
 20 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
selling Holder or Holders and the underwriter(s), if any, shall furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of
disposition of such securities as shall be required to effect the registered offering of their Registrable Securities. 
 SECTION 4.07.
Indemnification. 
 (a) In connection with each registration pursuant to Article IV, the Company agrees to indemnify and hold
harmless, to the fullest extent permitted by law, each selling Holder, their respective officers, directors, advisors, managers, agents and employees and each Person, if any, who controls any selling Holder within the meaning of Section 15 of
the Securities Act, and their respective officers, directors, advisors, managers, agents and employees, from and against: 

(i) any and all loss, liability, claim, damage and expense whatsoever (or actions or proceedings in respect thereof, whether or
not such indemnified party is a party thereto), as incurred (including reasonable costs of investigation and legal expenses) (each, a “Loss” and collectively “Losses”), arising out of an untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement (including any final, preliminary or summary Prospectus contained therein or any amendment thereof or supplement thereto or any documents incorporated by reference therein),
or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading (in the case of a Prospectus or preliminary Prospectus, in light of the circumstances under
which they were made); and 
 (ii) any and all Loss to the extent of the aggregate amount paid in settlement of any
litigation, or investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, if such settlement
is effected with the written consent of the Company, which consent shall not be unreasonably withheld; 
 provided, however, that, with
respect to any selling Holder, this indemnity shall not apply to any Loss to the extent arising out of an untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with written information furnished
to the Company by such selling Holder expressly for use in the Registration Statement (including any final, preliminary or summary Prospectus contained therein or any amendment thereof or supplement thereto). 

(b) Each selling Holder agrees, severally and not jointly, to indemnify and hold harmless, to the fullest extent permitted by law, the
Company, its directors, each 

  
 21 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
of its officers who signed a Registration Statement, and each other selling Holder, and each Person, if any, who controls the Company and any other selling Holder within the meaning of
Section 15 of the Securities Act, against any and all Loss, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (including any final, preliminary or summary
Prospectus contained therein or any amendment thereof or supplement thereto) in reliance upon and in conformity with written information furnished to the Company by such selling Holder expressly for use in the Registration Statement (including any
final, preliminary or summary Prospectus contained therein or any amendment thereof or supplement thereto); provided that no such selling Holder shall be liable under this Section 4.07 for any amounts exceeding the dollar amount of the
net proceeds received by such selling Holder, after deducting underwriting discounts and commissions, but before expenses, under the sale of the Registrable Securities giving rise to such indemnification obligation. 

(c) Each indemnified party shall give prompt notice to each indemnifying party of any action commenced against it in respect of which
indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve the indemnifying party from any liability it may have under this Agreement, except to the extent that the indemnifying party is prejudiced thereby.
If it so elects, after receipt of such notice, an indemnifying party, jointly with any other indemnifying parties receiving such notice, may assume the defense of such action with counsel chosen by it; provided, however, that the
indemnified party shall be entitled to participate in (but not control) the defense of such action with counsel chosen by it, the reasonable fees and expenses of which shall be paid by such indemnified party, unless a conflict would arise if one
counsel were to represent both the indemnified party and the indemnifying party, in which case the reasonable fees and expenses of counsel to the indemnified party shall be paid by the indemnifying party or parties. In no event shall the
indemnifying party or parties be liable for a settlement of an action with respect to which they have assumed the defense if such settlement is effected without the written consent of such indemnifying party, or for the reasonable fees and expenses
of more than one counsel for (i) the Company, its officers, directors and controlling persons as a group, and (ii) the selling Holders and their controlling persons as a group, in each case, in connection with any one action or separate
but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances; provided, however, that if, in the reasonable judgment of an indemnified party, a conflict of interest may exist
between such indemnified party and the Company or any other of such indemnified parties with respect to such claim, the indemnifying party shall be obligated to pay the reasonable fees and expenses of such additional counsel. 

SECTION 4.08. Contribution. 

(a) If the indemnification provided for in or pursuant to Section 4.07 is due in accordance with the terms hereof, but held by a court of
competent jurisdiction to 

  
 22 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
be unavailable or unenforceable in respect of any Loss referred to therein, then each applicable indemnifying party, in lieu of indemnifying such indemnified party, shall contribute to the amount
paid or payable by such indemnified party as a result of such Loss in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the
statements or omissions which result in such Loss as well as any other relevant equitable considerations. The relative fault of the indemnifying party on the one hand and of the indemnified party on the other shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party, and by such
party’s relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. In no event shall the liability of any selling Holder under this Section 4.08 be greater than the amount for which
such indemnifying party would have been obligated to pay by way of indemnification if the indemnification provided for under Section 4.07(a) had been available under the circumstances. 

(b) No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any Person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 4.08(b), each director of the Company, each officer of the Company who signed a Registration Statement, and each Person, if any,
who controls the Company or a selling Holder within the meaning of Section 15 of the Securities Act shall have the same rights to contribution as the Company or such selling Holder, as the case may be. 

SECTION 4.09. Representations, Warranties and Indemnities to Survive. The indemnity and contribution agreements contained in this
Article IV and the representations and warranties of the Company referred to in Section 4.04(l) shall remain operative and in full force and effect regardless of (i) any termination of any underwriting or agency agreement;
(ii) any investigation made by or on behalf of the selling Holder or Holders, the Company or any underwriter or agent or controlling Person; or (iii) the consummation of the sale or successive resales of the Registrable Securities. 

SECTION 4.10. Lock-Up Agreements. The Company agrees that, in connection with an underwritten offering in respect of which Registrable
Securities are being sold, if requested by the managing underwriter(s), it will not, directly or indirectly, sell, offer to sell, grant any option for the sale of, or otherwise dispose of, any securities which are the same as or similar to those
being registered, or which are convertible into or exchangeable or exercisable for such securities, during the period beginning seven (7) days before, and ending ninety (90) days (or such shorter period to which the selling Holder or
Holders are subject) after, the date of the closing under the underwriting agreement in connection therewith, to the extent the Company is timely notified in writing by the managing underwriters. The lock-up agreements set forth in this
Section 4.10 shall be subject to customary exceptions that may be set forth in a written underwriting agreement. 

  
 23 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 SECTION 4.11. Rule 144 Reporting. With a view to making available to the Holders
the benefits of certain rules and regulations of the SEC which may permit the sale of the Registrable Securities to the public without registration, the Company agrees, so long as it is subject to the periodic reporting requirements of the Exchange
Act, to use commercially reasonable efforts to: 
 (a) make and keep public information available, as those terms are understood and defined
in Rule 144(c)(1) or any similar or analogous rule promulgated under the Securities Act, at all times after the Issuance Date; 
 (b)
file with the SEC, in a timely manner, all reports and other documents required of the Company under the Exchange Act; and 
 (c) so long as
the Holders own any Registrable Securities, furnish to such Holders forthwith upon request: (i) in the event the Company is no longer subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, a written statement by
the Company as to its compliance with the reporting requirements of Rule 144 under the Securities Act and of the Exchange Act; (ii) in the event the Company is subject to the reporting requirements of Section 13 or 15(d) of the
Exchange Act, a copy of the most recent annual or quarterly report of the Company; and (iii) such other reports and documents as the Holders may reasonably request in availing themselves of any rule or regulation of the SEC allowing them to
sell any such securities without registration; provided, however, that the Company shall be deemed to have furnished any such document if it shall have timely made such document available on the SEC’s Electronic Data Gathering,
Analysis and Retrieval System, or a successor system. 
 SECTION 4.12. Additional Registration Rights. To the extent the Underlying
Stock is registered in a jurisdiction other than the United States, the Holders shall have equivalent registration rights with respect to the Registrable Securities to those set forth in this Agreement as applicable to such jurisdiction and its
securities laws, mutatis mutandis. 

  
 24 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 SECTION 4.13. No Inconsistent Agreements. The Company is not currently a party to, and
during the term of this Agreement will not enter into, any agreement which is inconsistent in any material respect with the rights granted to the Holders of Registrable Securities by this Agreement. 

ARTICLE V 
 Adjustments

 SECTION 5.01. No Adjustments for Routine Cash Dividends. No adjustments shall be made for the payment by the Company of cash
dividends, except for Specified Dividends as expressly provided below. 
 SECTION 5.02. Adjustments Upon Certain Transactions. If, at
any time after the Issuance Date, the Company (i) pays a dividend or makes any other distribution with respect to the Underlying Stock solely in Underlying Stock; (ii) subdivides the issued Underlying Stock; or (iii) combines the
issued Underlying Stock into a smaller number of shares, then the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to such adjustment by a fraction, (i) the numerator of which shall be the aggregate
number of shares of Underlying Stock issued immediately prior to such dividend, distribution, subdivision or combination, and the (ii) denominator of which shall be the aggregate number of shares of Underlying Stock issued immediately after
such dividend, distribution, subdivision or combination, and the product so obtained shall thereafter be the Exercise Price. Such adjustment shall become effective immediately after the effective date of such event retroactive to the record date, if
any, for such event. 
 SECTION 5.03. Dividends and Distributions. If, at any time after the Issuance Date, the Company pays a
dividend or makes any other distribution with respect to the Underlying Stock of securities, evidences of indebtedness, assets, cash, rights, warrants or other property (other than (x) any cash dividends other than Specified Dividends and
(y) any dividend or distribution subject to Section 5.02), including in connection with a Recapitalization Event, then the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to such adjustment by
a fraction, (i) the numerator of which shall be (A) the daily volume-weighted average price per share of the Underlying Stock for the last trading day before the Ex-date (or if the Underlying Stock is not then listed on a national
securities exchange or quotation system, the Fair Market Value of a share of Underlying Stock as of the applicable date) minus (B) the Fair Market Value of the items distributed in respect of each share of Underlying Stock in such
dividend or distribution, and (ii) the denominator of which shall be the daily volume-weighted average price per share of the Underlying Stock for the last trading day before the Ex-date (or if the Underlying Stock is not then listed on a
national securities exchange or quotation system, the Fair Market Value of a share of Underlying Stock as of the applicable date) (in each case the daily volume-weighted average price 

  
 25 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
per share of Underlying Stock shall be as reported by Bloomberg L.P., without regard to pre-open or after hours trading outside of any regular trading sessions for any such scheduled trading day
on such trading day), and the product so obtained shall thereafter be the Exercise Price. Such adjustment shall become effective immediately after the effective date of such event retroactive to the record date, if any, for such event. 

SECTION 5.04. Issuer Tender Offers. If, at any time after the Issuance Date, a publicly-announced tender offer made by the Company or
any of its subsidiaries for all or any portion of the Underlying Stock shall expire and tendering holders of Underlying Stock are paid aggregate consideration per share of Underlying Stock having a Fair Market Value, when paid, that exceeds the
daily volume-weighted average price per share of the Underlying Stock for the last trading day before the date on which such tender offer was first publicly announced (or if the Underlying Stock is not then listed on a national securities exchange
or quotation system, the Fair Market Value of a share of Underlying Stock as of such date) (the aggregate amount of such excess paid for all Underlying Stock acquired in such tender offer, the “Excess Tender Amount”), then the
Exercise Price for the unvested portion of any Warrant shall be adjusted by multiplying the Exercise Price in effect immediately prior to the expiration of such tender offer by a fraction, (i) the numerator of which shall be (A) the daily
volume-weighted average price per share of the Underlying Stock for the last trading day before the date on which such tender offer was first publicly announced (or if the Underlying Stock is not then listed on a national securities exchange or
quotation system, the Fair Market Value of a share of Underlying Stock as of such date) minus (B) the Premium Per Pro Forma Share, and (ii) the denominator of which shall be the daily volume-weighted average price per share of the
Underlying Stock for the last trading day before the date on which such tender offer was first publicly announced (or if the Underlying Stock is not then listed on a national securities exchange or quotation system, the Fair Market Value of a share
of Underlying Stock as of such date) (in each case the daily volume-weighted average price per share of Underlying Stock shall be as reported by Bloomberg L.P., without regard to pre-open or after hours trading outside of any regular trading
sessions for any such scheduled trading day on such trading day), and the product so obtained shall thereafter be the Exercise Price. As used herein, “Premium Per Pro Forma Share” means (x) the Excess Tender Amount divided by
(y) the number of shares of Underlying Stock issued upon the expiration of the tender offer after giving pro forma effect to the purchase of shares of Underlying Stock in the tender offer. 

SECTION 5.05. Recapitalization and Reorganization Events. 

(a) If, at any time after the Issuance Date, the Company effects (i) a recapitalization, reclassification or other capital reorganization
with respect to the Underlying Stock (a “Recapitalization Event”) or (ii) a consolidation, merger or similar extraordinary transaction of the Company with another Person, or the sale of all or substantially all of its assets to
another Person, where the Company is not the surviving party or where there is a change in or distribution with respect to the Underlying Stock (a 

  
 26 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
“Reorganization Event”), then, as a condition to and effective upon the consummation of such Recapitalization Event or Reorganization Event, lawful and adequate provisions shall
be made by the Company whereby the Holder of each Warrant (whether vested or unvested, but in the event such Recapitalization Event or Reorganization Event constitutes a Change of Control subject to the accelerated vesting provisions set forth in
Annex A) shall thereafter have the right to purchase and receive on exercise of such Warrant (subject to the vesting thereof in accordance with Annex A, including the accelerated vested provisions set forth therein), for an aggregate price equal to
the aggregate Exercise Price for all of the shares underlying such Warrant as in effect immediately before such transaction (allocated among the consideration receivable as a result of such Recapitalization Event or Reorganization Event in
proportion to the respective Fair Market Values of such consideration and subject to adjustment thereafter as contemplated by Section 5.05(b)), the same kind and amount of cash, securities or other property as such Holder would have had the
right to receive if such Holder had exercised such Warrant immediately before such Recapitalization Event or Reorganization Event and been entitled to participate therein. If and to the extent that the holders of Underlying Stock have the right to
elect the kind or amount of consideration receivable upon consummation of such Recapitalization Event or Reorganization Event, then the consideration that the Holder of each Warrant shall be entitled to receive upon exercise shall be specified by
such Holder, which specification shall be made by each Holder by the later of (A) ten (10) Business Days after the Holder is provided with a final version of all material information concerning such choice as is provided to the holders of
Underlying Stock, and (B) the last time at which the holders of Underlying Stock are permitted to make their specifications known to the Company; provided, however, that if a Holder fails to make any specification within such time
period, such Holder’s choice shall be deemed to be whatever choice is made by a plurality of all holders of Underlying Stock that are not affiliated with the Company (or, in the case of Reorganization Event, any other party thereto) and
affirmatively make an election (or of all such holders if none of them makes an election). 
 (b) In the event of any such Recapitalization
Event or Reorganization Event, the Company shall make appropriate provision to ensure that applicable provisions of this Agreement (including the provisions of Article IV and this Article V and the vesting provisions set forth in Annex A)
shall thereafter be binding on the surviving party to such transaction and applicable to any securities thereafter deliverable upon the exercise of Warrants. 

(c) The Company shall notify the Holder of each Warrant of any proposed Recapitalization Event or Reorganization Event reasonably prior to the
consummation thereof so as to provide such Holder with a reasonable opportunity prior to such consummation to exercise each Warrant in accordance with the terms and conditions hereof; provided, however, that in the case of a
transaction which requires notice to be given to the holders of Underlying Stock, the Holder of each Warrant shall be provided the same notice given to the holders of Underlying Stock. 

  
 27 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 (d) Notwithstanding anything to the contrary contained herein, in the event of a
Recapitalization Event or Reorganization Event, to the extent that one or more of the adjustments set forth in Section 5.02, 5.03 and/or 5.05 would be applicable to such Recapitalization Event or Reorganization Event, the adjustments set forth
in Sections 5.02, 5.03 and 5.05 shall be applied in the order in which the events described in such Sections occur; provided, however, that no adjustment pursuant to Section 5.02, 5.03 or 5.05, as applicable, shall be made
for an event in connection with such Recapitalization Event or Reorganization Event for which an adjustment has already been made. 

SECTION 5.06. Certain Other Events. If any event occurs as to which the provisions of this Article V are not strictly applicable
or, if strictly applicable, would not fairly protect the rights of the Holder(s) in accordance with the essential intent and principles of such provisions, then the Board shall make such adjustments in the application of such provisions, in
accordance with such essential intent and principles, as shall be reasonably necessary, in the good faith judgment of the Board, to protect such purchase rights as aforesaid. 

SECTION 5.07. Adjustment of Number of Shares Purchasable. Upon any adjustment of the Exercise Price pursuant to this Article V, the
total number of shares of Underlying Stock purchasable upon the exercise of each Warrant shall be adjusted by multiplying the number of shares of Underlying Stock purchasable immediately prior to such adjustment by a fraction, (i) the numerator
of which shall be the Exercise Price in effect immediately prior to such adjustment and (ii) the denominator of which shall be the Exercise Price resulting from such adjustment, and the product so obtained shall thereafter be the number of
shares of Underlying Stock purchasable upon exercise of such Warrant. 
 SECTION 5.08. Rounding of Calculations; Minimum Adjustments;
Effect of Adjustments. All calculations under this Article V shall be made to the nearest one-hundredth (1/100th) of a cent or share, as the case may be. Any provision of this Article V to the contrary notwithstanding, no adjustment in the
Exercise Price or the number of shares of Underlying Stock purchasable upon the exercise of any Warrant shall be made if the amount of such adjustment would be less than $0.01 or one share, but any such amount shall be carried forward and an
adjustment with respect thereto shall be made at the time of and together with any subsequent adjustment which, together with such amount and any other amount or amounts so carried forward, shall aggregate $0.01 or one share, or more. Except as
otherwise expressly provided herein, all adjustments to the Exercise Price, the number of shares of Underlying Stock or the type and amount of cash, securities or other property issuable upon the exercise of the Warrants shall apply to all Warrants
outstanding as of the effective date of such adjustment, whether vested or unvested. 

  
 28 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 SECTION 5.09. Notice of Adjustment. Whenever the Exercise Price, the number of shares
of Underlying Stock or the type and amount of cash, securities or other property issuable upon the exercise of the Warrants is adjusted, as herein provided, the Company shall promptly mail by first-class mail, postage prepaid, to each Holder of a
Warrant notice of such adjustment or adjustments setting forth the Exercise Price, the number of shares of Underlying Stock and/or the type and amount of cash, securities or other property issuable upon the exercise of each Warrant after such
adjustment, including a brief statement of the facts requiring such adjustment and setting forth the computation by which such adjustment was made. 

SECTION 5.10. Proceedings Prior to Any Action Requiring Adjustment. As a condition precedent to the taking of any action that would
require an adjustment pursuant to this Article V, the Company shall take any and all actions that may be necessary, including obtaining regulatory or other applicable securities exchange or shareholder approvals or exemptions, in order that the
Company may thereafter validly and legally issue as fully paid and nonassessable all Underlying Stock and, as applicable, all cash, securities and other property that the Holder of each Warrant is entitled to receive upon exercise of such Warrant.

 ARTICLE VI 
 Warrant
Transfer Books 
 SECTION 6.01. Warrant Transfer Books. Subject to Section 3.05: 

(a) The Company shall keep at its principal place of business a register in which the Company shall provide for the registration of Warrant
Certificates and of any exchanges or transfers of Warrant Certificates as herein provided. 
 (b) At the option of the Holder, Warrant
Certificates may be exchanged at such office and upon payment of the charges hereinafter provided. Whenever any Warrant Certificates are so surrendered for exchange, the Company shall execute and deliver the Warrant Certificates that the Holder
making the exchange is entitled to receive. 
 (c) All Warrant Certificates issued upon any registration of transfer or exchange of Warrant
Certificates shall be the valid obligations of the Company, evidencing the same obligations, and entitled to the same benefits under this Agreement, as the Warrant Certificates surrendered for such registration of transfer or exchange. 

(d) Every Warrant Certificate surrendered for registration of transfer or exchange shall (if so required by the Company) be duly endorsed, or
be accompanied by a written instrument of transfer in form reasonably satisfactory to the Company, duly executed by the Holder thereof or his attorney duly authorized in writing. 

  
 29 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 (e) No service charge shall be made to a Holder for any registration of transfer or exchange
of any Warrant Certificates, and the Company shall pay any taxes or other governmental charges that may be imposed in connection with any registration of the transfer or exchange of Warrant Certificates. 

(f) Any Warrant Certificate when duly endorsed in blank shall be deemed negotiable and when a Warrant Certificate shall have been so endorsed,
the Holder thereof may be treated by the Company and all other Persons dealing therewith as the absolute owner thereof for any purpose and as the Person entitled to exercise the rights represented thereby. 

ARTICLE VII 
 Warrant Holders

 SECTION 7.01. No Voting Rights. Prior to the exercise of the Warrants, no Holder of a Warrant Certificate, in its capacity as
such, shall be entitled to any rights of a shareholder of the Company, including the right to vote or to consent with respect to any matter. 

SECTION 7.02. Right of Action. All rights of action in respect of this Agreement are vested in the Holders of the Warrants, and any
Holder of Warrants, without the consent of the Holder of any other Warrant, may, on such Holder’s own behalf and for such Holder’s own benefit, enforce, and may institute and maintain any suit, action or proceeding against the Company
suitable to enforce, or otherwise in respect of, such Holder’s right to exercise, exchange or transfer such Holder’s Warrants in the manner provided in this Agreement or any other obligation of the Company under this Agreement. 

ARTICLE VIII 
 Representations
and Warranties 
 SECTION 8.01. Representations and Warranties of the Holder The Holder acknowledges that neither the issuance
and delivery of the Warrants, nor the sale, allotment, issuance and delivery of the Underlying Stock issuable upon the exercise thereof, have been registered under the Securities Act or under any applicable state securities laws, and, accordingly,
the Holder hereby represents and warrants to the Company as follows: 
 (a) The Holder (i) is acquiring the Warrants and, upon exercise
of the Warrants, will acquire any Underlying Stock issuable upon the exercise thereof pursuant to an exemption from registration under the Securities Act solely for investment with no present intention to distribute the Warrants or the Underlying
Stock to any Person in violation of the Securities Act or any applicable state securities laws and (ii) will not sell 

  
 30 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
or otherwise dispose of any of the Warrants or the Underlying Stock issuable upon the exercise thereof, except in compliance with the registration requirements or exemption provisions of the
Securities Act and any applicable state securities laws. 
 (b) The Holder (i) is an “accredited investor” (as such term is
defined in Rule 501(a) promulgated under the Securities Act) whose knowledge and experience in financial and business matters are such that the Holder is capable of evaluating the merits and risks of its investment in the Warrants or the
Underlying Stock issuable upon the exercise thereof, (ii) the Holder’s financial situation is such that it can afford to (A) bear the economic risk of holding the Warrants or the Underlying Stock issuable upon the exercise thereof for
an indefinite period of time, and (B) suffer complete loss of its investment in the Warrants or the Underlying Stock issuable upon the exercise thereof, and (iii)(A) the Company has made available to the Holder all documents and
information that the Holder has requested relating to an investment in the Company and (B) the Holder has had adequate opportunity to ask questions of, and receive answers from, the Company’s officers, employees, agents and other
representatives concerning the Company’s business, operations, financial condition, assets, liabilities and all other matters relevant to the Holder’s investment in the Warrants or the Underlying Stock issuable upon the exercise thereof;
provided, however, that the foregoing does not limit or modify the representations and warranties of the Company in Section 8.02 or the right of the Holder to rely thereon. 

SECTION 8.02. Representations and Warranties of the Company. SECTION 8.03. The Company hereby represents and warrants to Charter, as of
the Issuance Date, except as set forth in the SEC Documents filed with the SEC on or prior to the Issuance Date or as described in writing to Charter contemporaneous with the execution of this Agreement, as follows: 

(a) The Company is duly incorporated under the laws of England and Wales and has been in continuous existence since incorporation. Except as
would not reasonably be expected to have a Material Adverse Effect, each of the Company’s subsidiaries is duly incorporated or organized, validly existing and in good standing under the laws of its respective jurisdiction of organization. Each
of the Company and its subsidiaries has all requisite power and authority to carry on its business as now conducted and as presently proposed to be conducted, except for any failure of any subsidiaries to have such power and authority as would not
reasonably be expected to have a Material Adverse Effect. The Company has all requisite power and authority to execute, deliver and perform its obligations under this Agreement, to issue and deliver the Warrant Certificates hereunder and to allot
and issue the Underlying Stock upon exercise of the Warrants. Each of the Company and its subsidiaries is duly qualified to transact business as a foreign entity and is in good standing in each jurisdiction in which the failure to so qualify would
have a Material Adverse Effect. 

  
 31 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 (b) All corporate action on the part of the Company (including its Board, officers and
shareholders) necessary to authorize the execution, delivery and performance of this Agreement by the Company has been taken. This Agreement constitutes a valid and legally binding obligation of the Company, enforceable against the Company in
accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights
generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, and (iii) to the extent the indemnification provisions contained in Section 4.07 may be limited
by applicable United States federal or state securities laws. 
 (c) The directors of the Company have the requisite authority to issue and
allot, free from preemptive rights, the number of Ordinary Shares issuable upon exercise of the Warrants issuable hereunder on the Issuance Date and, upon issuance and allotment thereof, such Ordinary Shares will be duly and validly issued and fully
paid and non-assessable and issued free and clear of any lien, encumbrance, security interest, pledge, mortgage, hypothecation, charge, adverse claim, title retention agreement of any nature or kind, or other encumbrance (except any applicable
securities law restrictions). The offer, sale and issuance of the Warrants and the sale, issuance and allotment of the Underlying Stock upon exercise hereof (i) are not subject to and will not give rise to any preemptive rights or rights of
first refusal with respect thereto and (ii) assuming the accuracy of the representations and warranties of Charter contained herein, are and will be in compliance with all applicable United States federal and state securities laws. 

(d) With the exception of the filing of a Current Report on Form 8-K under the Exchange Act, no consent, approval, order, waiver, exemption or
authorization of, registration, declaration, filing or qualification with, certification, notice, application or report to, or expiration of any waiting period applicable to, any governmental authority, self-regulatory organization (including the
NASDAQ Stock Market or any other applicable national securities exchange) or any other third party is required on the part of the Company in connection with the execution and delivery of this Agreement or the offer, sale and issuance of the Warrants
hereunder, or the issuance and allotment of the Underlying Stock upon exercise thereof. 
 (e) (i) Neither the Company nor any of its
subsidiaries is in violation of or default under, and from December 31, 2015 through the Issuance Date has not received any notices of violation or default with respect to, (A) any provisions of the Company’s or any of its
subsidiaries’ constitutional or organizational documents, (B) any instrument, judgment, order, writ or decree of any court or governmental authority applicable to the Company or any of its subsidiaries, or (C) any note, indenture,
mortgage, lease, agreement, instrument or other contract to which it is a party or by which it is bound, except in the case of clauses (B) and (C) for such violations or defaults as would not, individually or in the aggregate, have a
Material Adverse Effect. 

  
 32 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 (ii) Neither the Company nor any of its subsidiaries is in violation of, and
the operation of the Company’s and its subsidiaries’ businesses as now conducted does not violate, any provision of any federal, state, local or foreign law, statute, rule or regulation applicable to the Company or its subsidiaries, except
for such violations as would not, individually or in the aggregate, have a Material Adverse Effect. 
 (iii) The execution,
delivery and performance of this Agreement by the Company and the offer, sale and issuance of the Warrants hereunder and the issuance and allotment of the Underlying Stock upon exercise thereof do not and will not conflict with, result in a
violation of or default under (with or without the passage of time and/or the giving of notice), or give rise to a right of termination, cancellation or acceleration of any obligation or to a loss of a material benefit under, (A) any provisions
of the Company’s or any of its subsidiaries’ constitutional or organizational documents, (B) any instrument, judgment, order, writ or decree of any court or governmental authority applicable to the Company or any of its subsidiaries,
or (C) any note, indenture, mortgage, lease, agreement, instrument or other contract to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound, except in the case of clauses
(B) and (C) for such violations or defaults as would not, individually or in the aggregate, have a Material Adverse Effect. 
 (f)
(i) The Company is current in its obligations to file and furnish all periodic reports with the SEC required to be filed or furnished by it under the Exchange Act. The Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2015, and any other reports, proxy statements and information the Company filed with or furnished to the SEC since December 31, 2015 (the “SEC Documents”), at the time of their filing or being furnished,
(A) did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and
(B) complied in all material respects with the applicable requirements of the Exchange Act and the Securities Act. 

(ii) The financial statements of the Company (whether audited or unaudited and including any notes thereto or schedules
included therein) included in the SEC Documents (the “Company Financial Statements”) (A) at the time of their filing or being furnished, complied as 

  
 33 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, (B) were prepared in accordance with U.S.
generally accepted accounting principles applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto or as otherwise permitted by Form 10-Q with respect to any Company Financial Statements filed on Form
10-Q), and (C) fairly presented in all material respects the consolidated financial position of the Company as of the dates thereof and the consolidated results of its operations and cash flows for the periods then ended. 

(iii) The Company is in compliance in all material respects with the applicable listing rules of the NASDAQ Stock Market and
has not received any written notice from the NASDAQ Stock Market asserting any material non-compliance with such rules. 

(iv) Since the date of the audited financial statements of the Company included in the Company’s Annual Report on Form
10-K for the fiscal year ended December 31, 2015, there has not been any event, change, occurrence or circumstance that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect. 

(g) As of September 29, 2016, the issued capital of the Company consisted solely of 189,681,265 Ordinary Shares. All issued Ordinary
Shares are duly authorized, validly issued, fully paid and non-assessable. Except for (a) 33,837,556 Ordinary Shares to be issued to employees pursuant to the terms of existing benefit plans disclosed in the SEC Documents filed publicly with
the SEC prior to the Issuance Date and (b) 8,000,000 Ordinary Shares issuable pursuant to warrants issued under that certain Warrant and Registration Rights Agreement dated June 29, 2016, by and between the Company and Comcast Cable
Communications Management, LLC, there are no (i) securities convertible into or exchangeable or exercisable for the Company’s shares, (ii) subscriptions, options, warrants, calls, rights, convertible securities or other contracts,
agreements or commitments of any kind or character obligating the Company to issue, transfer or sell any of its shares, or (C) any equity equivalents or any agreements, arrangements or understandings granting any Person any rights in the
Company similar to its shares. As of the Issuance Date, there are no outstanding obligations of the Company to repurchase, redeem or otherwise acquire any of the Company’s shares. 

(h) There is no action, suit, proceeding, arbitration, mediation, complaint, claim, charge or investigation pending or, to the Company’s
knowledge, currently threatened before any court, arbitrator, mediator or governmental agency or instrumentality against the Company, any of its subsidiaries or any officer or director of the Company or any of its subsidiaries: (i) that
questions the validity of, or the right of the 

  
 34 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
Company to enter into or perform its obligations under, this Agreement; or (ii) that would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

ARTICLE IX 
 Covenants 

SECTION 9.01. Issuance and Allotment on Exercise of Warrants. The Company covenants that it will at all times ensure that the directors
of the Company have the requisite authority to issue and allot, free from preemptive rights, such number of Ordinary Shares or other Underlying Stock as shall then be issuable upon the exercise of all Warrants issued hereunder. The Company covenants
that all Ordinary Shares or other Underlying Stock issuable upon exercise of the Warrants shall, upon such issue, be duly and validly issued and fully paid and non-assessable. 

SECTION 9.02. Notices. In case of: 

(a) any Change of Control, Recapitalization Event or Reorganization Event; 

(b) the declaration of (or setting of a record date for purpose of determining entitlement to receive) any dividend or distribution with
respect to the Underlying Stock; or 
 (c) the voluntary or involuntary dissolution, liquidation or winding-up of the Company; 

the Company shall give written notice thereof to each Holder of an outstanding Warrant not later than the earlier of (i) 10 Business Days prior to such
event or the record date with respect thereto (but in no event more than 20 Business Days prior to such event or record date) or (ii) such date as notice thereof is given to the holders of Underlying Stock; provided, however, that
if at the time any such notice is required to be given hereunder (x) the Company is subject to the reporting obligations of the Exchange Act and (y) such notice would result in the disclosure of material, non-public information regarding
the Company, the Company shall, prior to giving such notice to any Holder, consult with such Holder regarding such disclosure and only give such Holder written notice thereof in accordance with this Section 9.02 if such Holder confirms in
writing that it wants to receive such notice, whereupon such Holder shall hold any material, non-public information disclosed in such notice in confidence and use the same degree of care to maintain the confidentiality of such information as it uses
with respect to its own similar information, until such time as (A) such information has been publicly disclosed by or on behalf of the Company or (B) the Company notifies such Holder that such information no longer constitutes material,
non-public information. Any such notice shall also set forth such facts with respect to such event as shall be reasonably necessary to indicate the 

  
 35 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
effect of such event on the Exercise Price, the number of shares of Underlying Stock and the type and amount of cash, securities or other property issuable upon the exercise of the Warrants upon
the occurrence of such event. 
 SECTION 9.03. Regulatory Compliance. Notwithstanding anything herein to the contrary, if any Holder
determines that the consent, approval, order, waiver, exemption or authorization of, registration, declaration, filing or qualification with, certification, notice, application or report to, or expiration of any waiting period (including under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) applicable to, any governmental authority, self-regulatory organization (including the NASDAQ Stock Market or any other applicable national securities exchange) or any other third
party is required as a condition to the lawful and valid exercise or transfer of any Warrants held by such Holder, then, in each such case: (i) the Company shall reasonably cooperate with such Holder to obtain, make or file (as applicable), or
to assist the affected Person in obtaining, making or filing (as applicable), any such consent, approval, order, waiver, exemption, authorization, registration, declaration, filing, qualification, certification, notice, application, report or
waiting period expiration, including (A) promptly effecting all necessary notifications and other filings that are required to be made by the Company and (B) responding as promptly as reasonably practicable to all inquiries or requests
received by it or by the affected Person from any governmental authority, self-regulatory organization or other third party for initial or additional information or documentation in connection therewith; (ii) any time period provided herein for
the consummation of such exercise or transfer, as applicable, shall be suspended for the period of time during which any such consent, approval, order, waiver, exemption, authorization, registration, declaration, filing, qualification,
certification, notice, application, report or waiting period expiration is being pursued, but not beyond September 30, 2025; and (iii) if and to the extent that any such suspension causes the consummation thereof to occur after the
Expiration Date, then such Expiration Date shall be extended to (A) in the event of an exercise, the date of consummation thereof, and (B) in the event of a transfer, ten (10) days following the date of consummation thereof, but in
both (A) and (B) not beyond September 30, 2025. For the avoidance of doubt, nothing in this Section 9.03 shall require that the Company or any of its subsidiaries commit to any divestiture, license or hold separate or similar
arrangement with respect to the business, assets or properties of the Company or any of its subsidiaries. Any filings, notifications and/or responses by the Company will be in full compliance with all applicable legal requirements. The Company
shall, to the extent legally permissible, keep the Holder reasonably apprised of the status of any communications with, and any inquiries or requests for additional information from, the applicable governmental authority, self-regulatory
organization or other third party. The Holder shall pay any filing fees in connection with obtaining, making or filing (as applicable) any such consent, approval, order, waiver, exemption, authorization, registration, declaration, filing,
qualification, certification, notice, application, report or waiting period expiration, and the Company and the Holder shall otherwise each bear their respective costs and expenses in connection therewith. 

  
 36 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 SECTION 9.04. No Impairment. The Company will not, by amendment of its constitutional
documents or through any Recapitalization Event, Reorganization Event, dissolution, or other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Agreement or the Warrants, but will at all times in good
faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder(s) against impairment. 

ARTICLE X 
 Miscellaneous

 SECTION 10.01. Tax Matters. 

(a) The Company shall pay all transfer, stamp and other similar taxes that may be imposed in respect of the issuance or delivery of the
Warrants or in respect of the allotment, issuance or delivery by the Company of any Underlying Stock or other securities upon exercise of the Warrants with respect thereto or any future transfer thereof; provided, however, that the
Company shall not be required to pay any tax (including any applicable withholding tax) that may be imposed with respect to the issuance or delivery of any Warrants or the allotment, issuance or delivery of any Underlying Stock or other securities
to any Person other than the Holder, and no such allotment, issuance or delivery shall be made unless and until such other Person has paid to the Company the amount of any such tax, or has established to the satisfaction of the Company that such tax
has been paid. 
 (b) The Company and any of its Affiliates shall be entitled to deduct and withhold from any amounts payable or deemed
payable to the Holder, its Affiliates, or any transferee pursuant to this Agreement such amounts as may be required to be deducted and withheld with respect to the making of such payment under any applicable tax laws. To the extent that amounts are
so deducted and withheld and paid over to the appropriate governmental entity by the Company or any of its Affiliates, such amounts shall be treated for all purposes of this Agreement as having been paid to the party in respect of which the Company
or any of its Affiliates made such deduction and withholding. 
 (c) If the Holder, its Affiliates, or any transferee is entitled to an
exemption from or reduction of withholding tax with respect to any payments or deemed payments made under this Agreement, such party shall deliver to the Company or its Affiliate, as the case may be, at the time or times prescribed by applicable law
or as reasonably requested by the Company or its Affiliate, such properly completed and executed documentation reasonably requested by the Company or its Affiliate as will permit such payments to be made without withholding or at a reduced rate of
withholding. 

  
 37 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 SECTION 10.02. Surrender of Certificates. Any Warrant Certificate surrendered for
exercise or purchase shall be promptly canceled by the Company and shall not be reissued by the Company. The Company shall destroy such canceled Warrant Certificates. 

SECTION 10.03. Mutilated, Destroyed, Lost and Stolen Warrant Certificates. 

(a) If (i) any mutilated Warrant Certificate is surrendered to the Company or (ii) the Company receives evidence to its satisfaction
of the destruction, loss or theft of any Warrant Certificate, and there is delivered to the Company such appropriate affidavit of loss and a corporate bond of indemnity as may be reasonably required by the Company to save it harmless, then, in the
absence of notice to the Company that such Warrant Certificate has been acquired by a bona fide purchaser, the Company shall execute and deliver, in exchange for any such mutilated Warrant Certificate or in lieu of any such destroyed, lost or stolen
Warrant Certificate, a new Warrant Certificate of like tenor and for a like aggregate number of Warrants. 
 (b) Upon the issuance of any
new Warrant Certificate under this Section 10.03, the Company shall pay any taxes or other governmental charges that may be imposed in relation thereto and other expenses in connection therewith. 

(c) Every new Warrant Certificate executed and delivered pursuant to this Section 10.03 in lieu of any destroyed, lost or stolen Warrant
Certificate shall constitute an original contractual obligation of the Company, whether or not the destroyed, lost or stolen Warrant Certificate shall be at any time enforceable by anyone, and shall be entitled to the benefits of this Agreement
equally and proportionately with any and all other Warrant Certificates duly executed and delivered hereunder. 
 (d) The provisions of this
Section 10.03 are exclusive and shall preclude (to the extent lawful) all other rights or remedies with respect to the replacement of mutilated, destroyed, lost or stolen Warrant Certificates. 

SECTION 10.04. Removal of Legends. In the event (a) the shares of Underlying Stock are registered under the Securities Act or the
securities laws of any other jurisdiction or (b) the Company is presented with an opinion of counsel reasonably satisfactory to the Company that transfers of shares of Underlying Stock do not require registration under the Securities Act or the
securities laws of any other jurisdiction, the Company shall direct the Registrar, and the Registrar shall, upon surrender by a Holder of its certificates evidencing such shares of Underlying Stock to the Registrar, exchange such certificates for
certificates without the legends referred to in Section 3.06(b). 

  
 38 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 SECTION 10.05. Notices. Any notice, demand or delivery to the Company or the Holders
authorized by this Agreement shall be sufficiently given or made when mailed if sent by nationally recognized overnight delivery service (with tracking capability), by first-class mail, postage prepaid, or by email, in each case addressed to the
Company or the Holders, as applicable, as follows: 
  

					
		 	If to the Company:	  	ARRIS International plc
		 		  	3871 Lakefield Drive
		 		  	Suwanee, GA 30024
		 		  	Attention: General Counsel
		 		  	Email: Patrick.Macken@arris.com
			
		 	With a copy to:	  	Troutman Sanders LLP
		 		  	600 Peachtree Street, Suite 5200
		 		  	Atlanta, GA 30308
		 		  	Attention: Brinkley Dickerson
		 		  	Email: brink.dickerson@troutmansanders.com
			
		 	If to the Holders:	  	Charter Communications Operating, LLC
		 		  	c/o Charter Communications, Inc.
		 		  	400 Atlantic Street
		 		  	Stamford, CT 06901
		 		  	Attention: General Counsel
		 		  	Email: Rick.Dykhouse@Charter.com

 or such other address as shall have been furnished to the party giving or making such notice, demand or delivery. Any notice
required to be given by the Company to the Holders pursuant to this Agreement shall be made by mailing by registered mail, return receipt requested, to the Holders at their respective addresses shown on the register of the Company. Any notice that
is delivered in the manner herein provided shall be conclusively presumed to have been duly given (i) if sent by a nationally recognized overnight service, the Business Day immediately following the date sent, (ii) if sent by first-class
mail, three (3) Business Days following the date sent, and (iii) if sent by e-mail, the date sent if sent on a Business Day during business hours in the place of receipt and otherwise on the next Business Day (unless the sender receives an
automatic error message from the server of the intended recipient indicating that the applicable notice or communication has not been received by such intended recipient or delivery thereof is delayed for any reason whatsoever). 

SECTION 10.06. Applicable Law. This Agreement and each Warrant issued hereunder and all rights arising hereunder shall be governed by
the internal laws of the Commonwealth of Pennsylvania except to the extent that the corporate affairs doctrine applies the laws of England and Wales, in which event, but only to such extent, the laws of England and Wales shall apply. 

  
 39 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 SECTION 10.07. Persons Benefiting. This Agreement shall be binding upon and inure to
the benefit of the Company and the Holders from time to time of the Warrants and the Underlying Stock. Except as otherwise expressly provided herein, nothing in this Agreement is intended or shall be construed to confer upon any Person, other than
the Company and the Holders, any right, remedy or claim under or by reason of this Agreement or any part hereof. 
 SECTION 10.08.
Counterparts. This Agreement may be executed in any number of counterparts, including by means of facsimile and/or electronic mail transmission, each of which shall be deemed an original, but all of which together constitute one and the same
instrument. 
 SECTION 10.09. Amendments. Neither this Agreement nor any provisions hereof shall be waived, modified, changed,
discharged or terminated other than in a writing signed by each of the Company and each Holder. 
 SECTION 10.10. Headings. The
descriptive headings of the several Articles and Sections of this Agreement are inserted for convenience and shall not control or affect the meaning or construction of any of the provisions hereof. 

SECTION 10.11. Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on the part of the Company or a
Holder shall operate as a waiver of such right or otherwise prejudice the rights, powers or remedies of such Person. 
 SECTION 10.12.
Business Days. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding day that is a Business Day. 
 SECTION 10.13. Severability. The provisions of this Agreement shall be deemed severable and
the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application of such provision to any Person or any circumstance, is
invalid or unenforceable, (i) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (ii) the
remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of
such provision, or the application of such provision, in any other jurisdiction. 
 SECTION 10.14. Entire Agreement. This Agreement
constitutes the entire agreement between the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings, both written and oral, between the 

  
 40 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
parties with respect to the subject matter hereof. In the event of any conflict, discrepancy or ambiguity between the terms and conditions contained in this Agreement and any schedules or
attachments hereto, the terms and conditions contained in this Agreement shall take precedence. 

  
 41 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed, as of
the day and year first above written. 
  

					
	ARRIS INTERNATIONAL PLC
		
	By:	 	         /s/ David B. Potts

		 	Name:	 	David B. Potts
		 	Title:	 	Executive Vice President and Chief Financial Officer

  
 42 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed, as of
the day and year first above written. 
  

					
	CHARTER COMMUNICATIONS OPERATING, LLC
		
	By:	 	   /s/ Christopher L. Winfrey

		 	Name:	 	Christopher L. Winfrey
		 	Title:	 	Executive Vice President and Chief Financial Officer

  
 43 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 EXHIBIT A 

FORM OF FACE OF WARRANT CERTIFICATE 
 THESE
WARRANTS MAY ONLY BE TRANSFERRED IN ACCORDANCE WITH THE TERMS OF THE WARRANT AND REGISTRATION RIGHTS AGREEMENT REFERRED TO BELOW. NEITHER THESE WARRANTS NOR THE SECURITIES ISSUABLE UPON THE EXERCISE THEREOF HAVE BEEN REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS. SUCH WARRANTS AND SECURITIES MAY BE OFFERED, SOLD OR TRANSFERRED ONLY IN COMPLIANCE WITH THE REQUIREMENTS OF SUCH ACT AND OF ANY APPLICABLE STATE
SECURITIES LAWS AND SUBJECT TO THE PROVISIONS OF THE WARRANT AND REGISTRATION RIGHTS AGREEMENT DATED AS OF SEPTEMBER 30, 2016, BY AND AMONG ARRIS INTERNATIONAL PLC (THE “COMPANY”), CHARTER AND ANY OTHER HOLDERS OF WARRANTS ISSUED
THEREUNDER. A COPY OF SUCH WARRANT AND REGISTRATION RIGHTS AGREEMENT IS AVAILABLE AT THE OFFICES OF THE COMPANY. 
 WARRANTS TO PURCHASE ORDINARY SHARES
OF ARRIS INTERNATIONAL PLC 
  

					
	No.	 	Certificate for	  	Warrants

 This certifies that [INSERT NAME OF HOLDER], or registered assigns, is the registered holder of the number of
Warrants set forth above. Each Warrant entitles the holder thereof (the “Holder”), subject to the provisions contained herein and in the Warrant Agreement (as defined below), to purchase from ARRIS International plc, a company
incorporated under the laws of England and Wales (the “Company”), one ordinary share of nominal value £0.0l per share in the capital of the Company (“Ordinary Shares”), subject to adjustment upon the
occurrence of certain events specified in the Warrant Agreement, at the exercise price of $[INSERT EXERCISE PRICE] per share (the “Exercise Price”), subject to adjustment upon the occurrence of certain events specified in the
Warrant Agreement. 
 This Warrant Certificate is issued under and in accordance with the Warrant and Registration Rights Agreement, dated
as of September 30, 2016 (the “Warrant Agreement”), by and among the Company and Charter, and is subject to the terms and provisions contained in the Warrant Agreement, including the vesting requirements specified therein, to
all of which terms and provisions the Holder of this Warrant Certificate consents by acceptance hereof. The Warrant Agreement is hereby incorporated herein by reference and made a part hereof. Reference is hereby made to

  
 A-1 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
the Warrant Agreement for a full statement of the respective rights, limitations of rights, duties, obligations and immunities thereunder of the Company and the Holders of the Warrants.
Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in the Warrant Agreement. 
 This
Warrant Certificate shall terminate and be void as of the close of business on September 30, 2023, subject to extension as provided in the Warrant Agreement (the “Expiration Date”). 

As provided in the Warrant Agreement and subject to the terms and conditions therein set forth, the Warrants shall be exercisable in whole or
in part from time to time on any Business Day through and including the Expiration Date. 
 The Exercise Price and the number of Ordinary
Shares issuable upon the exercise of each Warrant are subject to adjustment as provided in the Warrant Agreement. 
 All Ordinary Shares
issuable by the Company upon the exercise of the Warrants shall, upon such issue, be duly and validly issued and fully paid and non-assessable. 

In order to exercise a Warrant, the registered holder hereof must surrender this Warrant Certificate at the principal place of business of the
Company, with the Exercise Subscription Form on the reverse hereof duly executed by the Holder hereof, with signature guaranteed as therein specified, all subject to the terms and conditions hereof and of the Warrant Agreement. 

The Company may require payment of a sum sufficient to pay certain taxes, assessments or other charges for which the Holder is responsible
pursuant to the Warrant Agreement. 
 No service charge shall be made to a Holder for any registration or exchange of the Warrant
Certificates, and the Company shall pay any taxes or other governmental charges payable in connection therewith. 
 Each taker and holder of
this Warrant Certificate by taking or holding the same, consents and agrees that this Warrant Certificate when duly endorsed in blank shall be deemed negotiable and that when this Warrant Certificate shall have been so endorsed, the holder hereof
may be treated by the Company and all other Persons dealing with this Warrant Certificate as the absolute owner hereof for any purpose and as the Person entitled to exercise the rights represented hereby. 

This Warrant Certificate and all rights arising hereunder shall be governed by the internal laws of the Commonwealth of Pennsylvania except to
the extent that the corporate affairs doctrine applies the laws of England and Wales, in which event, but only to such extent, the laws of England and Wales shall apply. 

  
 A-2 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 This Warrant Certificate and the Warrant Agreement are subject to amendment as provided in
the Warrant Agreement. 
 Copies of the Warrant Agreement are on file at the principal place of business of the Company and may be obtained
by writing to the Company at the following address: 
 ARRIS International plc 

3871 Lakefield Drive 
 Suwanee, GA 30024 

Fax: (678) 473-8470 
 Attention: General Counsel 

Dated: 
  

			
	ARRIS INTERNATIONAL PLC
		
	    By:	 	  

		 	Name:
		 	Title:

  
 A-3 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 FORM OF REVERSE OF WARRANT CERTIFICATE 

EXERCISE SUBSCRIPTION FORM 
 (To
be executed only upon exercise of Warrant) 
  

	To:	ARRIS INTERNATIONAL PLC (the “Company”) 

 The undersigned irrevocably exercises
             of the Warrants as follows: 
  

	 	❑	by Physical Delivery, subject to delivery of the aggregate Exercise Price for the Warrants being exercised, and the undersigned hereby directs that the applicable number of Ordinary Shares deliverable upon the exercise
of such Warrants be issued and registered in the name and delivered at the address specified below 

  

	 	❑	by Net Share Settlement, and the undersigned hereby directs that the applicable number of Ordinary Shares deliverable upon the exercise of such Warrants be issued and registered in the name and delivered at the address
specified below 

Name:                      
                             

Tax ID Number:                   
                

Address:                      
                          

                       
                                       

[Include if the Holder requests Net Cash Settlement: The undersigned hereby requests that this exercise be settled through Net Cash
Settlement, and, if the Company so agrees, the undersigned hereby instructs the Company to remit payment of the Net Cash Settlement to the following account: 

Bank
Name:                                        
 

ABA#:                      
                           

Account
#:                                        
   
 Swift
Code:                                        
  

Ref:                      
                                ] 

[Include if the Warrant is not exercised in full: Because the undersigned is not exercising all Warrants evidenced by this Warrant
Certificate, the undersigned hereby instructs the Company to deliver to the undersigned a new Warrant Certificate of like tenor and date for the balance of the Warrants.] 

The undersigned hereby represents and warrants to the Company that, as of the date hereof, the undersigned and its Affiliates beneficially own
                         

  
 A-4 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
Ordinary Shares (without giving effect to the exercise of these Warrants pursuant to this Exercise Subscription Form). 

Date: 
  

					
		 	  
	 	
		 	  (Signature of Registered Owner)1	 	
		 	  
	 	
		 	  (Street Address)	 	
		 	  
	 	
		 	  (City)                    (State)              
      (Zip Code)	 	

  

	1 	The signature must correspond with the name as written upon the face of the within Warrant Certificate in every particular, without alteration or any change whatsoever. 

  
 A-5 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 Annex A 

Exercise Price and Vesting Requirements 

The Exercise Prices of the Warrants shall be as follows: 

(i) For Warrants subject to vesting based on the 2016 Measurement Period and the 2017 Measurement Period, the Exercise Price shall be $28.54
per Ordinary Share (the “Initial Exercise Price”); and 
 (ii) For Warrants subject to vesting based on the 2018 Measurement
Period, the Exercise Price shall be the price (rounded to the nearest $0.01) equal to the lesser of: (1) the quotient obtained by dividing (a) the volume weighted average price per share of the Company’s Ordinary Shares on the NASDAQ
Stock Market for each of the ten (10) consecutive trading days ending on the trading day immediately preceding January 1, 2018 (as reported by Bloomberg L.P., without regard to pre-open or after hours trading outside of any regular trading
sessions for any such scheduled trading day on such trading day) by (b) ten (such ten-day average price calculated pursuant to this subpart (1), the “January 2018 Price”) and (2) the average of (x) the Initial Exercise Price
and (y) the January 2018 Price. 
 The Warrants will vest as follows: 

2016 Vesting 
 Warrants for 500,000 Ordinary Shares (the
“2016 Base Amount”) will vest as of December 31, 2016, if the total amount of Goods Sold pursuant to the MPA during the period from July 1, 2016 to and including December 31, 2016 (the “2016 Measurement
Period”) is at least $[*****]. 
 Warrants for up to an additional 500,000 Ordinary Shares will vest as of December 31, 2016 if
(i) the total amount of Goods Sold pursuant to the MPA during the 2016 Measurement Period is at least $[*****] and (ii) at least [*****]% (the “2016 Target Product Mix Percentage”) of the total Goods
Sold pursuant to the MPA during the 2016 Measurement Period are Network and Services Goods, in accordance with the following schedule: 
  

			
	 Amount of Goods Sold during the

2016 Measurement Period
	  	 Additional Warrants Vested

	 $[*****]
	  	50,000
	 $[*****]
	  	100,000
	 $[*****]
	  	150,000
	 $[*****]
	  	200,000
	 $[*****]
	  	250,000
	 $[*****]
	  	300,000
	 $[*****]
	  	350,000
	 $[*****]
	  	400,000
	 $[*****]
	  	450,000
	 $[*****] and beyond
	  	500,000

  
 Annex A-1 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 For purposes of clarity, the maximum number of Warrants that can vest in respect of the 2016 Measurement
Period is for 1,000,000 Ordinary Shares. 
 2017 Vesting 

Warrants for 1,000,000 Ordinary Shares (the “2017 Base Amount”) will vest as of December 31, 2017, if the total amount of Goods Sold
pursuant to the MPA during the period from January 1, 2017 to and including December 31, 2017 (the “2017 Measurement Period”) is at least $[*****]. 

Warrants for up to an additional 1,500,000 Ordinary Shares will vest as of December 31, 2017 if (i) the total amount of Goods Sold pursuant to the
MPA during the 2017 Measurement Period is at least $[*****] and (ii) at least [*****]% (the “2017 Target Product Mix Percentage”) of the total Goods Sold pursuant to the MPA during the 2017 Measurement
Period are Network and Services Goods, in accordance with the following schedule: 
  

			
	 Amount of Goods during the 2017

Measurement Period
	  	 Additional Warrants Vested

	 $[*****]
	  	150,000
	 $[*****]
	  	300,000
	 $[*****]
	  	450,000
	 $[*****]
	  	600,000
	 $[*****]
	  	750,000
	 $[*****]
	  	900,000
	 $[*****]
	  	1,050,000
	 $[*****]
	  	1,200,000
	 $[*****]
	  	1,350,000
	 $[*****] and beyond
	  	1,500,000

 For purposes of clarity, the maximum number of Warrants that can vest in respect of the 2017 Measurement Period is for
2,500,000 Ordinary Shares. 
 2018 Vesting 
 Warrants
for 1,000,000 Ordinary Shares (the “2018 Base Amount” and, together with the 2016 Base Amount and the 2017 Base Amount, each a “Base Amount”) will vest as of 

  
 Annex A-2 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 
December 31, 2018, if the total amount of Goods Sold pursuant to the MPA during the period from January 1, 2018 to and including December 31, 2018 (the “2018 Measurement
Period” and, together with the 2016 Measurement Period and the 2017 Measurement Period, each a “Measurement Period”) is at least $[*****]. 

Warrants for up to an additional 1,500,000 Ordinary Shares will vest as of December 31, 2018 if (i) the total amount of Goods Sold pursuant to the
MPA during the 2018 Measurement Period is at least $[*****] and (ii) at least [*****]% (the “2018 Target Product Mix Percentage” and, together with the 2016 Target Product Mix Percentage and the 2017 Target
Product Mix Percentage, each a “Target Product Mix Percentage”) of the total Goods Sold pursuant to the MPA during the 2018 Measurement Period are Network and Services Goods, in accordance with the following schedule: 

 

			
	 Amount of Goods Sold during the 2018

Measurement Period
	  	 Additional Warrants Vested

	 $[*****]
	  	150,000
	 $[*****]
	  	300,000
	 $[*****]
	  	450,000
	 $[*****]
	  	600,000
	 $[*****]
	  	750,000
	 $[*****]
	  	900,000
	 $[*****]
	  	1,050,000
	 $[*****]
	  	1,200,000
	 $[*****]
	  	1,350,000
	 $[*****]and beyond
	  	1,500,000

 Accelerated Vesting 
 In
the event that, on or before December 31, 2018, (x) Charter Communications (or any successor or permitted assignee of Charter Communications’ rights and obligations under the MPA) terminates the both the May 2012 MPA and the January
2012 MPA on account of a material breach thereof by the Company, which breach remains uncured following any applicable cure periods set forth in the MPA (a “Termination”), or (y) there occurs a Change of Control, then, in
addition to any Warrants that have already vested as of the date of such Termination or Change of Control (as the case may be, the “Trigger Date”), the following Warrants shall automatically vest as of, and become exercisable from
and after, the Trigger Date irrespective of the vesting provisions set forth above: 
  

	 	(i)	if the Trigger Date occurs during the 2016 Measurement Period, the 2016 Base Amount of Warrants plus the 2017 Base Amount of Warrants plus the 2018 Base Amount; or 

 

	 	(ii)	if the Trigger Date occurs during the 2017 Measurement Period, the 2017 Base Amount of Warrants plus the 2018 Base Amount; or 

  
 Annex A-3 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

	 	(iii)	if the Trigger Date occurs during the 2018 Measurement Period, the 2018 Base Amount. 

 Upon any acceleration of
the Warrants as provided above (A) upon a Termination, any remaining Warrants that have not vested (including as a result of such acceleration) shall be forfeited or (B) upon a Change of Control, any remaining Warrants that have not vested
(including as a result of such acceleration) shall continue to vest in accordance with the terms set forth above. 
 Notwithstanding any of the foregoing
accelerated vesting provisions, any accelerated vesting shall not increase the maximum number of Warrants that can vest in any Measurement Period. 

Guidelines for Calculating Vesting 
 All capitalized terms
used but not defined herein shall have the respective meanings ascribed to such terms in the MPA. In the event on any conflict between the terms of the May 2012 MPA and the January 2012 MPA, the terms of the May 2012 MPA shall be used. 

Goods shall be considered “Sold” if the Company has both (x) invoiced Charter Communications or its applicable Affiliate for the Goods
and (y) delivered the Goods, in each case in accordance with the terms set forth in the MPA. All determinations of the “amount” of Goods Sold shall be measured by reference to the net amount invoiced for the Goods reflecting
the application of any credits provided by the Company unless otherwise agreed in writing by the Parties. If an invoice is disputed or if a credit occurs subsequent to vesting for an applicable Measurement Period, the Parties shall cooperate in
order to adjust the economic effect of the portion, if any, of the vesting that would (or would not) have occurred. 
 “Network and Services
Goods” means all Goods (whether currently in existence, in development or developed hereafter) within the product lines and services that are included in the revenues of the Company’s Network & Cloud operating segment as
reflected in the Company’s audited financial statements for the year ended December 31, 2015 (as reported in the SEC Documents) or that are added to such operating segment thereafter. The revenues of the Company’s Network &
Cloud operating segment currently include the following product lines and services: CCAP/CMTS Edge Routers; PON and Deep Fiber (RFoG, RPHY); HFC Transmission Equipment (Headend Optics, Fiber Nodes, RF, actives and passives); Video Infrastructure
(Conditional Access, Video Processing, Storage and Streaming, Control Systems); Software managements systems (Work Force Management, Service Assurance, Subscriber Management, Advertising); Technical Support Services; and Professional Services. 

  
 Annex A-4 

 CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY 

[*****], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE 

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 
  

 The Company shall deliver written notice to the Holder of the number of Warrants vested during the applicable
Measurement Period not later than the January 31st immediately following the end of the applicable Measurement Period, provided that such notice shall not be conclusive and shall be subject to review and challenge by the Holder in the event of
any good faith dispute with respect to the calculation of the vested Warrants set forth therein. 
 For clarity, except as provided under “Accelerated
Vesting” above, (i) the amount of Goods Sold must equal or exceed the thresholds specified in the tables above in order for the corresponding number of Warrants to vest, (ii) no Goods Sold during the 2016 Measurement Period or the
2017 Measurement Period will be counted toward any future Measurement Period, and (iii) if the portion of total Goods Sold during a Measurement Period that are Network and Services Goods is less than the applicable Target Product Mix
Percentage, there will be no pro ration of the Warrants in excess of the applicable Base Amount. 

  
 Annex A-5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]